<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Cholesterol Therapies - Competitive Landscape Analysis</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <style>
        /* Custom animations that Tailwind doesn't provide */
        @keyframes fadeInRow {
            from { opacity: 0; transform: translateY(10px); }
            to { opacity: 1; transform: translateY(0); }
        }
        @keyframes pulse {
            0%, 100% { opacity: 0.5; transform: scale(0.95); }
            50% { opacity: 0.8; transform: scale(1.1); }
        }
        @keyframes slideIn {
            from { opacity: 0; transform: translateX(-10px); }
            to { opacity: 1; transform: translateX(0); }
        }
        .animate-fade-in-row { animation: fadeInRow 0.3s ease forwards; }
        .animate-pulse-glow { animation: pulse 3s ease-in-out infinite; }
        .animate-slide-in { animation: slideIn 0.6s ease-out forwards; }
        
        /* Staggered animations */
        .stagger-1 { animation-delay: 0.1s; }
        .stagger-2 { animation-delay: 0.2s; }
        .stagger-3 { animation-delay: 0.3s; }
        .stagger-4 { animation-delay: 0.4s; }
        .stagger-5 { animation-delay: 0.5s; }
        
        /* Custom scrollbar */
        ::-webkit-scrollbar { width: 8px; height: 8px; }
        ::-webkit-scrollbar-track { @apply bg-gray-100 dark:bg-gray-800 rounded; }
        ::-webkit-scrollbar-thumb { @apply bg-gray-400 dark:bg-gray-600 rounded hover:bg-gray-500 dark:hover:bg-gray-500; }
        
        /* Glass effect */
        .glass {
            background: rgba(255, 255, 255, 0.75);
            backdrop-filter: blur(20px);
            -webkit-backdrop-filter: blur(20px);
        }
        .dark .glass {
            background: rgba(17, 24, 39, 0.75);
        }
    </style>
</head>
<body class="bg-gray-50 dark:bg-gray-900 transition-all duration-300">
    <!-- Fixed Header -->
    <header class="fixed top-0 left-0 right-0 z-50 glass border-b border-gray-200 dark:border-gray-700 shadow-lg">
        <div class="max-w-7xl mx-auto px-4 sm:px-6 lg:px-8">
            <div class="flex justify-between items-center py-4">
                <!-- Logo -->
                <div class="flex items-center space-x-3">
                    <div class="relative">
                        <img src="leaf.png" alt="Leaf Intelligence" class="h-12 w-12 relative z-10">
                        <div class="absolute inset-0 bg-gradient-to-r from-green-400 to-cyan-400 opacity-20 blur-xl animate-pulse-glow"></div>
                    </div>
                    <div>
                        <div class="text-xl font-light bg-gradient-to-r from-green-600 to-cyan-600 dark:from-green-400 dark:to-cyan-400 bg-clip-text text-transparent">
                            Leaf Intelligence
                        </div>
                        <div class="text-xs text-gray-600 dark:text-gray-400 font-light">
                            Cholesterol Therapies Analysis
                        </div>
                    </div>
                </div>

                <!-- Navigation -->
                <nav class="hidden md:flex items-center space-x-1 bg-gray-100/50 dark:bg-gray-800/50 p-1.5 rounded-lg backdrop-blur-sm">
                    <button class="nav-tab px-5 py-2 rounded-md text-sm font-medium transition-all duration-200 text-gray-600 dark:text-gray-400 hover:text-gray-900 dark:hover:text-white hover:bg-white/50 dark:hover:bg-gray-700/50 active" onclick="showTab('overview')">
                        Overview
                    </button>
                    <button class="nav-tab px-5 py-2 rounded-md text-sm font-medium transition-all duration-200 text-gray-600 dark:text-gray-400 hover:text-gray-900 dark:hover:text-white hover:bg-white/50 dark:hover:bg-gray-700/50" onclick="showTab('approved')">
                        Competitors
                    </button>
                    <button class="nav-tab px-5 py-2 rounded-md text-sm font-medium transition-all duration-200 text-gray-600 dark:text-gray-400 hover:text-gray-900 dark:hover:text-white hover:bg-white/50 dark:hover:bg-gray-700/50" onclick="showTab('comparison')">
                        Comparison
                    </button>
                         <button class="nav-tab px-5 py-2 rounded-md text-sm font-medium transition-all duration-200 text-gray-600 dark:text-gray-400 hover:text-gray-900 dark:hover:text-white hover:bg-white/50 dark:hover:bg-gray-700/50" onclick="showTab('ema')">
                        EMA vs FDA
                    </button>
                    </button>
                         <button class="nav-tab px-5 py-2 rounded-md text-sm font-medium transition-all duration-200 text-gray-600 dark:text-gray-400 hover:text-gray-900 dark:hover:text-white hover:bg-white/50 dark:hover:bg-gray-700/50" onclick="showTab('compliance')">
                        Compliance
                    </button>
                </nav>

                <!-- Theme Toggle -->
                <!-- <button onclick="toggleTheme()" class="relative w-14 h-7 rounded-full bg-gray-200 dark:bg-gray-700 transition-all duration-300 shadow-inner hover:shadow-md">
                    <div class="absolute top-0.5 left-0.5 w-6 h-6 rounded-full bg-white dark:bg-gray-900 shadow-lg transform transition-transform duration-300 dark:translate-x-7 flex items-center justify-center">
                        <svg class="w-4 h-4 text-yellow-500 dark:hidden" fill="currentColor" viewBox="0 0 24 24">
                            <path d="M12 7a5 5 0 100 10 5 5 0 000-10z"/>
                        </svg>
                        <svg class="w-4 h-4 text-indigo-400 hidden dark:block" fill="currentColor" viewBox="0 0 24 24">
                            <path d="M21 12.79A9 9 0 1111.21 3 7 7 0 0021 12.79z"/>
                        </svg>
                    </div>
                </button> -->
            </div>
        </div>
    </header>

    <!-- Main Container with padding for fixed header -->
    <div class="pt-20 min-h-screen">
        <!-- Overview Tab -->
        <div class="tab-content active" id="overview">
            <div class="max-w-7xl mx-auto px-4 sm:px-6 lg:px-8 py-8">
                <!-- Hero Section -->
                <div class="glass rounded-2xl p-8 mb-8 border border-gray-200 dark:border-gray-700">
                    <h1 class="text-3xl font-light mb-2 text-gray-900 dark:text-white">
                        Cholesterol Therapy Landscape 2025
                    </h1>
                    <p class="text-sm text-gray-600 dark:text-gray-400">
                        Comprehensive regulatory and market analysis of lipid-lowering therapies
                    </p>
                </div>

                <!-- Executive Summary -->
                <div class="glass rounded-2xl p-8 mb-8 border border-gray-200 dark:border-gray-700">
                    <h2 class="flex items-center gap-2 mb-6 text-xl font-light text-gray-900 dark:text-white">
                        <span>ðŸŽ¯</span> Executive Summary
                    </h2>
                    <div class="grid grid-cols-1 lg:grid-cols-2 gap-8">
                        <div>
                            <h3 class="mb-4 text-lg font-light text-gray-800 dark:text-gray-200">Current Market Reality</h3>
                            <ul class="space-y-3">
                                <li class="text-sm text-gray-600 dark:text-gray-400 animate-slide-in">
                                    <strong class="text-gray-900 dark:text-white">Statins remain foundation</strong> - 90% of patients start here (generic, ~$10/month)
                                </li>
                                <li class="text-sm text-gray-600 dark:text-gray-400 animate-slide-in stagger-1">
                                    <strong class="text-gray-900 dark:text-white">PCSK9 antibodies proven but underused</strong> - High cost ($5,800/year) limits access
                                </li>
                                <li class="text-sm text-gray-600 dark:text-gray-400 animate-slide-in stagger-2">
                                    <strong class="text-gray-900 dark:text-white">Inclisiran's unique position</strong> - Only twice-yearly therapy, NHS deal shows potential
                                </li>
                                <li class="text-sm text-gray-600 dark:text-gray-400 animate-slide-in stagger-3">
                                    <strong class="text-gray-900 dark:text-white">Step therapy barriers</strong> - Must fail 2-3 drugs before accessing advanced therapies
                                </li>
                            </ul>
                        </div>
                        <div>
                            <h3 class="mb-4 text-lg font-light text-gray-800 dark:text-gray-200">What's Coming Next</h3>
                            <ul class="space-y-3">
                                <li class="text-sm text-gray-600 dark:text-gray-400 animate-slide-in stagger-4">
                                    <strong class="text-gray-900 dark:text-white">Oral PCSK9 revolution (2025-26)</strong> - Daily pills matching injectable efficacy
                                </li>
                                <li class="text-sm text-gray-600 dark:text-gray-400 animate-slide-in stagger-5">
                                    <strong class="text-gray-900 dark:text-white">Price competition intensifying</strong> - Biosimilars coming 2028, generics 2033+
                                </li>
                                <li class="text-sm text-gray-600 dark:text-gray-400 animate-slide-in" style="animation-delay: 0.6s;">
                                    <strong class="text-gray-900 dark:text-white">Gene editing on horizon</strong> - One-time cure potential by 2030
                                </li>
                                <li class="text-sm text-gray-600 dark:text-gray-400 animate-slide-in" style="animation-delay: 0.7s;">
                                    <strong class="text-gray-900 dark:text-white">Combination strategies emerging</strong> - Triple/quadruple therapy for ultra-low LDL
                                </li>
                            </ul>
                        </div>
                    </div>
                    <div class="mt-6 p-4 bg-gradient-to-r from-indigo-50 to-purple-50 dark:from-indigo-900/20 dark:to-purple-900/20 rounded-lg border-l-4 border-indigo-500">
                        <p class="text-sm text-gray-700 dark:text-gray-300">
                            <span class="text-lg mr-2">ðŸ’¡</span>
                            <strong>Key Insight:</strong> The market is transitioning from "injectable vs oral" to "convenience vs compliance vs cost". Inclisiran's twice-yearly dosing offers guaranteed compliance, oral PCSK9i offers convenience, and biosimilars will offer cost savings. Success will depend on proving real-world outcomes and securing favorable payer agreements.
                        </p>
                    </div>
                </div>

                <!-- Key Terms and Treatment Pathway Grid -->
                <div class="grid grid-cols-1 lg:grid-cols-2 gap-8 mb-8">
                    <!-- Understanding Key Terms -->
                    <div class="glass rounded-xl p-6 border border-gray-200 dark:border-gray-700">
                        <h3 class="flex items-center gap-2 mb-4 text-lg font-light text-gray-900 dark:text-white">
                            <span>ðŸ“š</span> Understanding Key Terms & Metrics
                        </h3>
                        <div class="grid grid-cols-2 gap-3">
                            <div class="p-3 bg-gray-50 dark:bg-gray-800 rounded-lg">
                                <div class="text-xs font-medium text-indigo-600 dark:text-indigo-400 mb-1">What is LDL-C?</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    <strong class="text-gray-900 dark:text-white">Low-Density Lipoprotein Cholesterol</strong><br>
                                    "Bad cholesterol" that builds up in arteries<br>
                                    Goal: &lt;70 mg/dL (high-risk)<br>
                                    Goal: &lt;55 mg/dL (very high-risk)
                                </div>
                            </div>
                            <div class="p-3 bg-gray-50 dark:bg-gray-800 rounded-lg">
                                <div class="text-xs font-medium text-indigo-600 dark:text-indigo-400 mb-1">What is MACE?</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    <strong class="text-gray-900 dark:text-white">Major Adverse Cardiovascular Events</strong><br>
                                    Combined measure of heart attacks, strokes, CV death, and stents/bypass
                                </div>
                            </div>
                            <div class="p-3 bg-gray-50 dark:bg-gray-800 rounded-lg">
                                <div class="text-xs font-medium text-indigo-600 dark:text-indigo-400 mb-1">What is PCSK9?</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    <strong class="text-gray-900 dark:text-white">Proprotein Convertase Subtilisin/Kexin 9</strong><br>
                                    Protein that destroys LDL receptors. Blocking = more LDL removal
                                </div>
                            </div>
                            <div class="p-3 bg-gray-50 dark:bg-gray-800 rounded-lg">
                                <div class="text-xs font-medium text-indigo-600 dark:text-indigo-400 mb-1">Dosing Abbreviations</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    <strong class="text-gray-900 dark:text-white">Q2W</strong> = Every 2 weeks<br>
                                    <strong class="text-gray-900 dark:text-white">Q4W</strong> = Monthly<br>
                                    <strong class="text-gray-900 dark:text-white">Q6M</strong> = Every 6 months
                                </div>
                            </div>
                        </div>
                    </div>

                    <!-- Treatment Pathway -->
                    <div class="glass rounded-xl p-6 border border-gray-200 dark:border-gray-700">
                        <h3 class="flex items-center gap-2 mb-4 text-lg font-light text-gray-900 dark:text-white">
                            <span>ðŸ”„</span> Treatment Decision Pathway
                        </h3>
                        <div class="flex items-center justify-between gap-2 mb-4">
                            <div class="flex-1 p-3 bg-white dark:bg-gray-800 rounded-lg border border-gray-200 dark:border-gray-600 hover:shadow-md transition-shadow">
                                <div class="w-8 h-8 bg-gradient-to-r from-indigo-500 to-purple-500 rounded-full flex items-center justify-center text-white text-sm font-medium mb-2">1</div>
                                <div class="text-xs font-medium text-gray-900 dark:text-white">Start Statin</div>
                                <div class="text-xs text-gray-500 dark:text-gray-400">30-50% LDLâ†“</div>
                            </div>
                            <span class="text-gray-400 dark:text-gray-600">â†’</span>
                            <div class="flex-1 p-3 bg-white dark:bg-gray-800 rounded-lg border border-gray-200 dark:border-gray-600 hover:shadow-md transition-shadow">
                                <div class="w-8 h-8 bg-gradient-to-r from-indigo-500 to-purple-500 rounded-full flex items-center justify-center text-white text-sm font-medium mb-2">2</div>
                                <div class="text-xs font-medium text-gray-900 dark:text-white">Add Ezetimibe</div>
                                <div class="text-xs text-gray-500 dark:text-gray-400">+15-20% LDLâ†“</div>
                            </div>
                            <span class="text-gray-400 dark:text-gray-600">â†’</span>
                            <div class="flex-1 p-3 bg-white dark:bg-gray-800 rounded-lg border border-gray-200 dark:border-gray-600 hover:shadow-md transition-shadow">
                                <div class="w-8 h-8 bg-gradient-to-r from-indigo-500 to-purple-500 rounded-full flex items-center justify-center text-white text-sm font-medium mb-2">3</div>
                                <div class="text-xs font-medium text-gray-900 dark:text-white">Consider Bempedoic</div>
                                <div class="text-xs text-gray-500 dark:text-gray-400">+18-25% LDLâ†“</div>
                            </div>
                            <span class="text-gray-400 dark:text-gray-600">â†’</span>
                            <div class="flex-1 p-3 bg-gradient-to-r from-indigo-100 to-purple-100 dark:from-indigo-900/30 dark:to-purple-900/30 rounded-lg border-2 border-indigo-500 dark:border-indigo-400 shadow-md">
                                <div class="w-8 h-8 bg-gradient-to-r from-indigo-600 to-purple-600 rounded-full flex items-center justify-center text-white text-sm font-medium mb-2">4</div>
                                <div class="text-xs font-medium text-gray-900 dark:text-white">PCSK9 Therapy</div>
                                <div class="text-xs text-gray-500 dark:text-gray-400">+50-60% LDLâ†“</div>
                            </div>
                        </div>
                        <div class="p-3 bg-amber-50 dark:bg-amber-900/20 rounded-lg border-l-4 border-amber-500">
                            <p class="text-xs text-gray-700 dark:text-gray-300">
                                <strong>Note:</strong> Each step typically requires 6-12 weeks to assess response. Payers usually require documentation of inadequate response before approving next step.
                            </p>
                        </div>
                    </div>
                </div>

                    <!-- Pipeline Table -->
                     <div class="glass rounded-2xl p-6 border border-gray-200 dark:border-gray-700 mb-8 ">
                    <h3 class="text-sm font-medium mb-3 text-gray-700 dark:text-gray-300">Pipeline & Emerging Therapies</h3>
                    <div class="overflow-x-auto">
                        <table class="w-full">
                            <thead>
                                <tr class="bg-gray-50 dark:bg-gray-800">
                                    <th class="px-4 py-3 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Drug/Company</th>
                                    <th class="px-4 py-3 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Mechanism</th>
                                    <th class="px-4 py-3 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Status</th>
                                    <th class="px-4 py-3 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Key Events</th>
                                </tr>
                            </thead>
                            <tbody class="divide-y divide-gray-200 dark:divide-gray-700">
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-4 py-3 text-sm text-gray-900 dark:text-white"><strong>LIB003</strong><br>LIB Therapeutics</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Monthly PCSK9 adnectin</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">BLA accepted<br>PDUFA: Dec 12, 2025</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Head-to-head vs inclisiran ongoing</td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-4 py-3 text-sm text-gray-900 dark:text-white"><strong>MK-0616</strong><br>Merck</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Oral PCSK9 inhibitor</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Phase 3 ongoing</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Global program underway</td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-4 py-3 text-sm text-gray-900 dark:text-white"><strong>AZD0780</strong><br>AstraZeneca</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Oral PCSK9 inhibitor</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Phase 2b complete</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">PURSUIT trial met endpoints</td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-4 py-3 text-sm text-gray-900 dark:text-white"><strong>VERVE-101</strong><br>Eli Lilly</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Gene editing</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Clinical hold lifted</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">FDA hold resolved Oct 2023</td>
                                </tr>
                            </tbody>
                        </table>
                    </div>
            </div>

                <!-- Compliance History Timeline -->
                <div class="glass rounded-2xl p-6 mb-8 border border-gray-200 dark:border-gray-700">
                    <h3 class="mb-2 text-xl font-light text-gray-900 dark:text-white">Compliance History & Regulatory Analysis</h3>
                    <p class="text-xs text-gray-600 dark:text-gray-400 mb-6">Minimal regulatory friction, mostly CMC-related issues</p>
                    
                    <div class="relative pl-8">
                        <!-- Timeline line -->
                        <div class="absolute left-3 top-0 bottom-0 w-0.5 bg-gradient-to-b from-transparent via-indigo-300 dark:via-indigo-600 to-transparent"></div>
                        
                        <!-- Timeline items -->
                        <div class="relative mb-8">
                            <div class="absolute -left-5 w-4 h-4 bg-red-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-indigo-600 dark:text-indigo-400 mb-1">DECEMBER 2020</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Inclisiran Complete Response Letter</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    <strong class="text-gray-900 dark:text-white">Issue:</strong> Third-party manufacturing facility inspection<br>
                                    <strong class="text-gray-900 dark:text-white">Context:</strong> COVID-19 restricted FDA access<br>
                                    <strong class="text-gray-900 dark:text-white">Important:</strong> No clinical/safety/efficacy concerns
                                </div>
                            </div>
                        </div>

                        <div class="relative mb-8">
                            <div class="absolute -left-5 w-4 h-4 bg-green-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-indigo-600 dark:text-indigo-400 mb-1">DECEMBER 21, 2021</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Inclisiran CRL Resolution</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    <strong class="text-gray-900 dark:text-white">Resolution:</strong> Facility inspection completed<br>
                                    <strong class="text-gray-900 dark:text-white">Outcome:</strong> Full FDA approval granted
                                </div>
                            </div>
                        </div>

                        <div class="relative mb-8">
                            <div class="absolute -left-5 w-4 h-4 bg-red-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-indigo-600 dark:text-indigo-400 mb-1">NOVEMBER 2022</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">VERVE-101 Clinical Hold</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    <strong class="text-gray-900 dark:text-white">Product:</strong> PCSK9 gene editor<br>
                                    <strong class="text-gray-900 dark:text-white">Reason:</strong> First-in-human safety review<br>
                                    <strong class="text-gray-900 dark:text-white">Requirements:</strong> Additional safety data
                                </div>
                            </div>
                        </div>

                        <div class="relative">
                            <div class="absolute -left-5 w-4 h-4 bg-green-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-indigo-600 dark:text-indigo-400 mb-1">OCTOBER 2023</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">VERVE-101 Hold Lifted</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    <strong class="text-gray-900 dark:text-white">Resolution:</strong> FDA reviewed additional materials<br>
                                    <strong class="text-gray-900 dark:text-white">Outcome:</strong> US studies permitted to continue<br>
                                    <strong class="text-gray-900 dark:text-white">Note:</strong> Eli Lilly acquired assets July 2025
                                </div>
                            </div>
                        </div>
                    </div>
                </div>

                <!-- Market Evolution -->
                <div class="hidden glass rounded-2xl p-6 mb-8 border border-gray-200 dark:border-gray-700">
                    <h3 class="mb-6 text-xl font-light text-gray-900 dark:text-white">5-10 Year Market Evolution</h3>
                    
                    <div class="space-y-4">
                        <div class="flex items-start space-x-4 p-4 bg-white dark:bg-gray-800 rounded-lg hover:shadow-lg transition-shadow">
                            <div class="flex-shrink-0 w-24 text-xs font-medium text-indigo-600 dark:text-indigo-400">2025-2027</div>
                            <div class="flex-grow">
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Oral Revolution</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    â€¢ MK-0616, AZD0780 enter market<br>
                                    â€¢ LIB003 approved as monthly option<br>
                                    â€¢ Inclisiran ORION-4 validates CV benefit<br>
                                    â€¢ Price competition intensifies
                                </div>
                            </div>
                        </div>

                        <div class="flex items-start space-x-4 p-4 bg-white dark:bg-gray-800 rounded-lg hover:shadow-lg transition-shadow">
                            <div class="flex-shrink-0 w-24 text-xs font-medium text-amber-600 dark:text-amber-400">2028-2030</div>
                            <div class="flex-grow">
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Biosimilar Era</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    â€¢ PCSK9 mAb biosimilars arrive<br>
                                    â€¢ Oral PCSK9i dominate new prescriptions<br>
                                    â€¢ Gene editing potentially approved for FH<br>
                                    â€¢ Combination pills emerge
                                </div>
                            </div>
                        </div>

                        <div class="flex items-start space-x-4 p-4 bg-white dark:bg-gray-800 rounded-lg hover:shadow-lg transition-shadow">
                            <div class="flex-shrink-0 w-24 text-xs font-medium text-green-600 dark:text-green-400">2030-2035</div>
                            <div class="flex-grow">
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Precision Medicine</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    â€¢ Personalized therapy selection<br>
                                    â€¢ Gene editing for broader populations<br>
                                    â€¢ Ultra-low cost generics<br>
                                    â€¢ Primary prevention expansion
                                </div>
                            </div>
                        </div>
                    </div>
                </div>

                <!-- Technical Specifications Table -->
                <div class="glass rounded-2xl p-6 border border-gray-200 dark:border-gray-700">
                    <h3 class="mb-4 text-xl font-light text-gray-900 dark:text-white">Technical & Clinical Specifications</h3>
                    <div class="overflow-x-auto">
                        <table class="w-full">
                            <thead>
                                <tr class="bg-gray-50 dark:bg-gray-800">
                                    <th class="px-4 py-3 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Drug</th>
                                    <th class="px-4 py-3 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Mechanism</th>
                                    <th class="px-4 py-3 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">LDL-C Reduction</th>
                                    <th class="px-4 py-3 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Dosing</th>
                                    <th class="px-4 py-3 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Administration</th>
                                    <th class="px-4 py-3 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">CV Outcomes</th>
                                </tr>
                            </thead>
                            <tbody class="divide-y divide-gray-200 dark:divide-gray-700">
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-4 py-3 text-sm text-gray-900 dark:text-white font-medium">Inclisiran</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">siRNA</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">50-52%</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Q6M</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">SC by HCP</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Pending (2026)</td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-4 py-3 text-sm text-gray-900 dark:text-white font-medium">Repatha</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">PCSK9 mAb</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">60%</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Q2W/Monthly</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">SC self-injection</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">15% MACE â†“</td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-4 py-3 text-sm text-gray-900 dark:text-white font-medium">Praluent</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">PCSK9 mAb</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">45-60%</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Q2W/Q4W</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">SC self-injection</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">15% MACE â†“</td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-4 py-3 text-sm text-gray-900 dark:text-white font-medium">Bempedoic Acid</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">ACL inhibitor</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">18-25%</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Daily</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Oral</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">13% MACE â†“</td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-4 py-3 text-sm text-gray-900 dark:text-white font-medium">MK-0616</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Oral PCSK9i</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">60%</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Daily</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Oral</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Phase 3</td>
                                </tr>
                            </tbody>
                        </table>
                    </div>
                </div>
            </div>
        </div>

        <div class="tab-content hidden" id="emaold">
              <div class="max-w-7xl mx-auto px-4 sm:px-6 lg:px-8 py-8">
                <!-- EMA vs FDA Comparison -->
                <div class="glass rounded-2xl p-6 mb-8 border border-gray-200 dark:border-gray-700">
                    <h3 class="mb-6 text-xl font-light text-gray-900 dark:text-white">EMA vs FDA: Regulatory Comparison</h3>
                    
                    <!-- Inclisiran -->
                    <div class="mb-6">
                        <h3 class="text-sm font-medium mb-3 text-gray-700 dark:text-gray-300">Inclisiran (LeqvioÂ®) - Novartis</h3>
                        <div class="grid grid-cols-1 md:grid-cols-2 gap-4">
                            <div class="p-4 bg-gradient-to-r from-blue-50 to-blue-100 dark:from-blue-900/20 dark:to-blue-800/20 rounded-lg border-l-4 border-blue-600">
                                <div class="font-medium mb-2 text-gray-900 dark:text-white">ðŸ‡ªðŸ‡º EMA Approval</div>
                                <div class="text-xs space-y-1 text-gray-600 dark:text-gray-400">
                                    <p><strong class="text-gray-900 dark:text-white">Date:</strong> December 9, 2020</p>
                                    <p><strong class="text-gray-900 dark:text-white">Indication:</strong> Primary hypercholesterolaemia or mixed dyslipidaemia</p>
                                    <p><strong class="text-gray-900 dark:text-white">Administration:</strong> HCP dosing every 6 months</p>
                                </div>
                            </div>
                            <div class="p-4 bg-gradient-to-r from-red-50 to-red-100 dark:from-red-900/20 dark:to-red-800/20 rounded-lg border-l-4 border-red-600">
                                <div class="font-medium mb-2 text-gray-900 dark:text-white">ðŸ‡ºðŸ‡¸ FDA Approval</div>
                                <div class="text-xs space-y-1 text-gray-600 dark:text-gray-400">
                                    <p><strong class="text-gray-900 dark:text-white">Date:</strong> December 21, 2021 (12 months after EMA)</p>
                                    <p><strong class="text-gray-900 dark:text-white">Initial CRL:</strong> Manufacturing facility inspection issues (COVID)</p>
                                    <p><strong class="text-gray-900 dark:text-white">Label Expansion:</strong> July 2023 - broader primary hyperlipidaemia use</p>
                                </div>
                            </div>
                        </div>
                        <div class="mt-3 p-3 bg-gray-50 dark:bg-gray-800 rounded-lg">
                            <p class="text-xs text-gray-700 dark:text-gray-300">
                                <strong>Divergence:</strong> EU approved one year earlier. US delay solely due to COVID-era facility inspection issues, not clinical concerns. Both await ORION-4 outcomes data (2026).
                            </p>
                        </div>
                    </div>

                    <!-- Pipeline Table -->
                    <h3 class="text-sm font-medium mb-3 text-gray-700 dark:text-gray-300">Pipeline & Emerging Therapies</h3>
                    <div class="overflow-x-auto">
                        <table class="w-full">
                            <thead>
                                <tr class="bg-gray-50 dark:bg-gray-800">
                                    <th class="px-4 py-3 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Drug/Company</th>
                                    <th class="px-4 py-3 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Mechanism</th>
                                    <th class="px-4 py-3 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Status</th>
                                    <th class="px-4 py-3 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Key Events</th>
                                </tr>
                            </thead>
                            <tbody class="divide-y divide-gray-200 dark:divide-gray-700">
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-4 py-3 text-sm text-gray-900 dark:text-white"><strong>LIB003</strong><br>LIB Therapeutics</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Monthly PCSK9 adnectin</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">BLA accepted<br>PDUFA: Dec 12, 2025</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Head-to-head vs inclisiran ongoing</td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-4 py-3 text-sm text-gray-900 dark:text-white"><strong>MK-0616</strong><br>Merck</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Oral PCSK9 inhibitor</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Phase 3 ongoing</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Global program underway</td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-4 py-3 text-sm text-gray-900 dark:text-white"><strong>AZD0780</strong><br>AstraZeneca</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Oral PCSK9 inhibitor</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Phase 2b complete</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">PURSUIT trial met endpoints</td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-4 py-3 text-sm text-gray-900 dark:text-white"><strong>VERVE-101</strong><br>Eli Lilly</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Gene editing</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Clinical hold lifted</td>
                                    <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">FDA hold resolved Oct 2023</td>
                                </tr>
                            </tbody>
                        </table>
                    </div>
                </div>

                  <div class="reference-card">
            <h3>Overview of Regulatory Divergence Patterns</h3>
            <p style="font-size: 13px; color: var(--text-secondary); margin-bottom: 16px;">
                Analysis of approved cholesterol therapies reveals systematic differences in regulatory approach between EMA and FDA:
            </p>
            
            <div class="stat-grid">
                <div class="stat-card">
                    <div class="stat-value">12</div>
                    <div class="stat-label">Months Average EMA Lead</div>
                    <div style="font-size: 11px; color: var(--text-secondary); margin-top: 4px;">For inclisiran approval</div>
                </div>
                <div class="stat-card">
                    <div class="stat-value">3</div>
                    <div class="stat-label">FDA Manufacturing CRLs</div>
                    <div style="font-size: 11px; color: var(--text-secondary); margin-top: 4px;">Inclisiran, gene editing holds</div>
                </div>
                <div class="stat-card">
                    <div class="stat-value">2-4</div>
                    <div class="stat-label">Years to CV Outcomes Label</div>
                    <div style="font-size: 11px; color: var(--text-secondary); margin-top: 4px;">Post-approval for both agencies</div>
                </div>
                <div class="stat-card">
                    <div class="stat-value">6mo vs 5yr</div>
                    <div class="stat-label">Pediatric Age Difference</div>
                    <div style="font-size: 11px; color: var(--text-secondary); margin-top: 4px;">Evinacumab: EMA vs FDA</div>
                </div>
            </div>

            <h3>Drug-by-Drug Regulatory Comparison</h3>
            
            <!-- Inclisiran -->
            <div class="compliance-event">
                <div class="compliance-event-header">
                    <div class="compliance-event-title">Inclisiran (LeqvioÂ®) - siRNA</div>
                    <div class="compliance-event-date">Novartis</div>
                </div>
                <div class="agency-comparison">
                    <div class="agency-box ema">
                        <div class="agency-header">ðŸ‡ªðŸ‡º EMA Approval</div>
                        <div style="font-size: 13px;">
                            <p><strong>Date:</strong> December 9, 2020</p>
                            <p><strong>Initial Indication:</strong> Adults with primary hypercholesterolaemia (HeFH and non-FH) or mixed dyslipidaemia</p>
                            <p><strong>Positioning:</strong> Add-on to statins/other LLTs or when statins not tolerated</p>
                            <p><strong>Administration:</strong> HCP dosing at Day 1, Month 3, then every 6 months</p>
                        </div>
                    </div>
                    <div class="agency-box fda">
                        <div class="agency-header">ðŸ‡ºðŸ‡¸ FDA Approval</div>
                        <div style="font-size: 13px;">
                            <p><strong>Date:</strong> December 21, 2021 (12 months after EMA)</p>
                            <p><strong>Initial CRL:</strong> December 2020 - third-party manufacturing facility inspection issues</p>
                            <p><strong>Label Expansion:</strong> July 2023 - broadened to allow earlier use in primary hyperlipidaemia</p>
                            <p><strong>Key Issue:</strong> COVID-era facility access, not clinical/safety/efficacy concerns</p>
                        </div>
                    </div>
                </div>
                <div class="info-box" style="margin-top: 12px;">
                    <p style="font-size: 12px; margin: 0;"><strong>Divergence Analysis:</strong> EU approved with broad adult dyslipidaemia label one year earlier. US approval delayed solely due to CMC/inspection issues during COVID, not data concerns. FDA later aligned with broader labeling in 2023. Both agencies await ORION-4 outcomes data (expected 2026).</p>
                </div>
            </div>

            <!-- Repatha -->
            <div class="compliance-event">
                <div class="compliance-event-header">
                    <div class="compliance-event-title">RepathaÂ® (evolocumab) - PCSK9 mAb</div>
                    <div class="compliance-event-date">Amgen</div>
                </div>
                <div class="agency-comparison">
                    <div class="agency-box ema">
                        <div class="agency-header">ðŸ‡ªðŸ‡º EMA Approval</div>
                        <div style="font-size: 13px;">
                            <p><strong>Date:</strong> 2015</p>
                            <p><strong>Initial Indication:</strong> Primary hypercholesterolaemia, HoFH, mixed dyslipidaemia</p>
                            <p><strong>CV Risk Reduction:</strong> Added to label based on FOURIER outcomes</p>
                        </div>
                    </div>
                    <div class="agency-box fda">
                        <div class="agency-header">ðŸ‡ºðŸ‡¸ FDA Approval</div>
                        <div style="font-size: 13px;">
                            <p><strong>Date:</strong> 2015</p>
                            <p><strong>CV Outcomes Update:</strong> 2017 - reduction of MI, stroke, coronary revascularisation</p>
                            <p><strong>Evidence Base:</strong> FOURIER trial data</p>
                        </div>
                    </div>
                </div>
                <div class="info-box" style="margin-top: 12px;">
                    <p style="font-size: 12px; margin: 0;"><strong>Divergence Analysis:</strong> Remarkably aligned approval timing. Both agencies granted CV risk reduction claims following FOURIER outcomes data, with FDA updating label in 2017.</p>
                </div>
            </div>

            <!-- Praluent -->
            <div class="compliance-event">
                <div class="compliance-event-header">
                    <div class="compliance-event-title">PraluentÂ® (alirocumab) - PCSK9 mAb</div>
                    <div class="compliance-event-date">Sanofi/Regeneron</div>
                </div>
                <div class="agency-comparison">
                    <div class="agency-box ema">
                        <div class="agency-header">ðŸ‡ªðŸ‡º EMA Approval</div>
                        <div style="font-size: 13px;">
                            <p><strong>Date:</strong> 2015</p>
                            <p><strong>Current Label:</strong> Includes CV risk reduction for ASCVD</p>
                            <p><strong>Pediatric Extension:</strong> HeFH from age 8</p>
                        </div>
                    </div>
                    <div class="agency-box fda">
                        <div class="agency-header">ðŸ‡ºðŸ‡¸ FDA Approval</div>
                        <div style="font-size: 13px;">
                            <p><strong>Date:</strong> 2015</p>
                            <p><strong>CV Outcomes:</strong> May 2019 - reduction of MI, stroke, unstable angina</p>
                            <p><strong>Evidence Base:</strong> ODYSSEY OUTCOMES trial</p>
                        </div>
                    </div>
                </div>
                <div class="info-box" style="margin-top: 12px;">
                    <p style="font-size: 12px; margin: 0;"><strong>Divergence Analysis:</strong> Both approved simultaneously in 2015. FDA added CV outcomes language in 2019 (4 years post-approval) based on ODYSSEY OUTCOMES. EMA includes broader dyslipidaemia use and pediatric indication.</p>
                </div>
            </div>

            <!-- Bempedoic Acid -->
            <div class="compliance-event">
                <div class="compliance-event-header">
                    <div class="compliance-event-title">Bempedoic Acid - Oral ACL Inhibitor</div>
                    <div class="compliance-event-date">Esperion (US: Nexletol/Nexlizet; EU: Nilemdo/Nustendi)</div>
                </div>
                <div class="agency-comparison">
                    <div class="agency-box ema">
                        <div class="agency-header">ðŸ‡ªðŸ‡º EMA Approval</div>
                        <div style="font-size: 13px;">
                            <p><strong>Initial:</strong> LDL-C lowering indication</p>
                            <p><strong>March 2024:</strong> CHMP positive opinion for CV risk reduction</p>
                            <p><strong>Note:</strong> Combination pill available (Nustendi)</p>
                        </div>
                    </div>
                    <div class="agency-box fda">
                        <div class="agency-header">ðŸ‡ºðŸ‡¸ FDA Approval</div>
                        <div style="font-size: 13px;">
                            <p><strong>2020:</strong> Approved for LDL-C lowering</p>
                            <p><strong>March 22, 2024:</strong> CV risk-reduction label expansion</p>
                            <p><strong>Products:</strong> Both Nexletol and Nexlizet received CV indication</p>
                        </div>
                    </div>
                </div>
                <div class="info-box" style="margin-top: 12px;">
                    <p style="font-size: 12px; margin: 0;"><strong>Divergence Analysis:</strong> Both agencies moved simultaneously in March 2024 to add CV outcomes following CLEAR Outcomes trial. EU historically had combination pill first. Regulatory alignment achieved on outcomes recognition.</p>
                </div>
            </div>

            <!-- Evinacumab -->
            <div class="compliance-event">
                <div class="compliance-event-header">
                    <div class="compliance-event-title">Evinacumab (EvkeezaÂ®) - ANGPTL3 mAb for HoFH</div>
                    <div class="compliance-event-date">Regeneron/Ultragenyx</div>
                </div>
                <div class="agency-comparison">
                    <div class="agency-box ema">
                        <div class="agency-header">ðŸ‡ªðŸ‡º EMA Approval</div>
                        <div style="font-size: 13px;">
                            <p><strong>Date:</strong> June 17, 2021</p>
                            <p><strong>Age Range:</strong> <span class="highlight-positive">â‰¥6 months</span></p>
                            <p><strong>Population:</strong> Adults, adolescents, and children with HoFH</p>
                            <p><strong>Administration:</strong> IV every 4 weeks</p>
                        </div>
                    </div>
                    <div class="agency-box fda">
                        <div class="agency-header">ðŸ‡ºðŸ‡¸ FDA Approval</div>
                        <div style="font-size: 13px;">
                            <p><strong>Date:</strong> February 11, 2021 (4 months before EMA)</p>
                            <p><strong>Initial Age:</strong> â‰¥12 years</p>
                            <p><strong>Pediatric Extension:</strong> March 2023 to <span class="highlight-neutral">â‰¥5 years</span></p>
                            <p><strong>Administration:</strong> IV every 4 weeks</p>
                        </div>
                    </div>
                </div>
                <div class="info-box" style="margin-top: 12px;">
                    <p style="font-size: 12px; margin: 0;"><strong>Divergence Analysis:</strong> FDA approved first but EMA granted significantly broader pediatric access (6 months vs 5 years). This represents the largest age divergence in the class, with EMA showing greater willingness to approve for very young patients in ultra-rare disease.</p>
                </div>
            </div>


        </div>

                </div>
        </div>

        <div class="tab-content hidden" id="ema">
    <div class="max-w-7xl mx-auto px-4 sm:px-6 lg:px-8 py-8">
        <!-- Hero Section -->
        <div class="glass rounded-2xl p-8 mb-8 border border-gray-200 dark:border-gray-700">
            <h1 class="text-3xl font-light mb-2 text-gray-900 dark:text-white">
                EMA vs FDA Regulatory Analysis
            </h1>
            <p class="text-sm text-gray-600 dark:text-gray-400">
                Comparing approval pathways and regulatory divergence in cholesterol therapies
            </p>
        </div>

        <!-- Executive Summary -->
        <div class="glass rounded-2xl p-8 mb-8 border border-gray-200 dark:border-gray-700">
            <h2 class="flex items-center gap-2 mb-6 text-xl font-light text-gray-900 dark:text-white">
                <span>ðŸŽ¯</span> Regulatory Divergence Overview
            </h2>
            <div class="grid grid-cols-1 lg:grid-cols-2 gap-8">
                <div>
                    <h3 class="mb-4 text-lg font-light text-gray-800 dark:text-gray-200">Key Patterns Observed</h3>
                    <ul class="space-y-3">
                        <li class="text-sm text-gray-600 dark:text-gray-400 animate-slide-in">
                            <strong class="text-gray-900 dark:text-white">EMA leads by 12 months average</strong> - Inclisiran approved Dec 2020 vs Dec 2021 FDA
                        </li>
                        <li class="text-sm text-gray-600 dark:text-gray-400 animate-slide-in stagger-1">
                            <strong class="text-gray-900 dark:text-white">FDA focus on manufacturing</strong> - 3 CRLs/holds for CMC issues, not clinical
                        </li>
                        <li class="text-sm text-gray-600 dark:text-gray-400 animate-slide-in stagger-2">
                            <strong class="text-gray-900 dark:text-white">EMA broader pediatric access</strong> - Evinacumab from 6 months vs FDA 5 years
                        </li>
                        <li class="text-sm text-gray-600 dark:text-gray-400 animate-slide-in stagger-3">
                            <strong class="text-gray-900 dark:text-white">Aligned on outcomes</strong> - Both require 2-4 years post-approval for CV claims
                        </li>
                    </ul>
                </div>
                <div>
                    <h3 class="mb-4 text-lg font-light text-gray-800 dark:text-gray-200">Regulatory Implications</h3>
                    <ul class="space-y-3">
                        <li class="text-sm text-gray-600 dark:text-gray-400 animate-slide-in stagger-4">
                            <strong class="text-gray-900 dark:text-white">COVID impact on FDA</strong> - Facility inspections delayed multiple approvals
                        </li>
                        <li class="text-sm text-gray-600 dark:text-gray-400 animate-slide-in stagger-5">
                            <strong class="text-gray-900 dark:text-white">Harmonized CV standards</strong> - MACE endpoint requirements similar
                        </li>
                        <li class="text-sm text-gray-600 dark:text-gray-400 animate-slide-in" style="animation-delay: 0.6s;">
                            <strong class="text-gray-900 dark:text-white">Gene editing caution</strong> - Both agencies requiring extensive safety data
                        </li>
                        <li class="text-sm text-gray-600 dark:text-gray-400 animate-slide-in" style="animation-delay: 0.7s;">
                            <strong class="text-gray-900 dark:text-white">Label expansion timing</strong> - Post-approval evidence similarly evaluated
                        </li>
                    </ul>
                </div>
            </div>
            <div class="mt-6 p-4 bg-gradient-to-r from-indigo-50 to-purple-50 dark:from-indigo-900/20 dark:to-purple-900/20 rounded-lg border-l-4 border-indigo-500">
                <p class="text-sm text-gray-700 dark:text-gray-300">
                    <span class="text-lg mr-2">ðŸ’¡</span>
                    <strong>Key Insight:</strong> While approval timing differs, both agencies maintain similar safety and efficacy standards. EMA's earlier approvals often reflect different risk tolerance and inspection priorities rather than lower standards. FDA's manufacturing focus has caused delays but not clinical rejections.
                </p>
            </div>
        </div>

  

        <!-- Drug-by-Drug Comparisons -->
        <div class="glass rounded-2xl p-6 mb-8 border border-gray-200 dark:border-gray-700">
            <h3 class="mb-6 text-xl font-light text-gray-900 dark:text-white">Drug-by-Drug Regulatory Comparison</h3>
            
            <!-- Inclisiran -->
            <div class="mb-6 p-4 bg-white dark:bg-gray-800 rounded-lg hover:shadow-lg transition-shadow">
                <div class="flex items-start justify-between mb-4">
                    <div>
                        <h4 class="text-lg font-light text-gray-900 dark:text-white">Inclisiran (LeqvioÂ®)</h4>
                        <p class="text-xs text-gray-500 dark:text-gray-400">Novartis - siRNA therapy</p>
                    </div>
                    <span class="px-3 py-1 text-xs font-medium bg-gradient-to-r from-indigo-100 to-purple-100 dark:from-indigo-900/30 dark:to-purple-900/30 text-indigo-700 dark:text-indigo-300 rounded-full">12 Month Gap</span>
                </div>
                <div class="grid grid-cols-1 md:grid-cols-2 gap-4">
                    <div class="p-3 bg-blue-50 dark:bg-blue-900/20 rounded-lg border-l-4 border-blue-500">
                        <div class="flex items-center gap-2 mb-2">
                            <span>ðŸ‡ªðŸ‡º</span>
                            <span class="font-medium text-sm text-gray-900 dark:text-white">EMA Approval</span>
                        </div>
                        <div class="space-y-1 text-xs text-gray-600 dark:text-gray-400">
                            <p><strong class="text-gray-900 dark:text-white">Date:</strong> December 9, 2020</p>
                            <p><strong class="text-gray-900 dark:text-white">Indication:</strong> Primary hypercholesterolaemia or mixed dyslipidaemia</p>
                            <p><strong class="text-gray-900 dark:text-white">Administration:</strong> HCP dosing every 6 months</p>
                        </div>
                    </div>
                    <div class="p-3 bg-red-50 dark:bg-red-900/20 rounded-lg border-l-4 border-red-500">
                        <div class="flex items-center gap-2 mb-2">
                            <span>ðŸ‡ºðŸ‡¸</span>
                            <span class="font-medium text-sm text-gray-900 dark:text-white">FDA Approval</span>
                        </div>
                        <div class="space-y-1 text-xs text-gray-600 dark:text-gray-400">
                            <p><strong class="text-gray-900 dark:text-white">Date:</strong> December 21, 2021</p>
                            <p><strong class="text-gray-900 dark:text-white">Initial CRL:</strong> Manufacturing facility issues (COVID)</p>
                            <p><strong class="text-gray-900 dark:text-white">Label Expansion:</strong> July 2023 - broader use</p>
                        </div>
                    </div>
                </div>
                <div class="mt-3 p-2 bg-amber-50 dark:bg-amber-900/20 rounded border-l-4 border-amber-500">
                    <p class="text-xs text-gray-700 dark:text-gray-300">
                        <strong>Key Divergence:</strong> EU approved one year earlier. US delay solely due to COVID-era facility inspection issues, not clinical concerns.
                    </p>
                </div>
            </div>

            <!-- Repatha -->
            <div class="mb-6 p-4 bg-white dark:bg-gray-800 rounded-lg hover:shadow-lg transition-shadow">
                <div class="flex items-start justify-between mb-4">
                    <div>
                        <h4 class="text-lg font-light text-gray-900 dark:text-white">RepathaÂ® (evolocumab)</h4>
                        <p class="text-xs text-gray-500 dark:text-gray-400">Amgen - PCSK9 mAb</p>
                    </div>
                    <span class="px-3 py-1 text-xs font-medium bg-gradient-to-r from-green-100 to-emerald-100 dark:from-green-900/30 dark:to-emerald-900/30 text-green-700 dark:text-green-300 rounded-full">Aligned</span>
                </div>
                <div class="grid grid-cols-1 md:grid-cols-2 gap-4">
                    <div class="p-3 bg-blue-50 dark:bg-blue-900/20 rounded-lg border-l-4 border-blue-500">
                        <div class="flex items-center gap-2 mb-2">
                            <span>ðŸ‡ªðŸ‡º</span>
                            <span class="font-medium text-sm text-gray-900 dark:text-white">EMA Approval</span>
                        </div>
                        <div class="space-y-1 text-xs text-gray-600 dark:text-gray-400">
                            <p><strong class="text-gray-900 dark:text-white">Date:</strong> 2015</p>
                            <p><strong class="text-gray-900 dark:text-white">Initial:</strong> Primary hypercholesterolaemia, HoFH</p>
                            <p><strong class="text-gray-900 dark:text-white">CV Risk:</strong> Added based on FOURIER</p>
                        </div>
                    </div>
                    <div class="p-3 bg-red-50 dark:bg-red-900/20 rounded-lg border-l-4 border-red-500">
                        <div class="flex items-center gap-2 mb-2">
                            <span>ðŸ‡ºðŸ‡¸</span>
                            <span class="font-medium text-sm text-gray-900 dark:text-white">FDA Approval</span>
                        </div>
                        <div class="space-y-1 text-xs text-gray-600 dark:text-gray-400">
                            <p><strong class="text-gray-900 dark:text-white">Date:</strong> 2015</p>
                            <p><strong class="text-gray-900 dark:text-white">CV Update:</strong> 2017 - MI, stroke reduction</p>
                            <p><strong class="text-gray-900 dark:text-white">Evidence:</strong> FOURIER trial data</p>
                        </div>
                    </div>
                </div>
                <div class="mt-3 p-2 bg-green-50 dark:bg-green-900/20 rounded border-l-4 border-green-500">
                    <p class="text-xs text-gray-700 dark:text-gray-300">
                        <strong>Key Divergence:</strong> Remarkably aligned approval timing. Both agencies granted CV risk reduction claims following FOURIER outcomes.
                    </p>
                </div>
            </div>

            <!-- Praluent -->
            <div class="mb-6 p-4 bg-white dark:bg-gray-800 rounded-lg hover:shadow-lg transition-shadow">
                <div class="flex items-start justify-between mb-4">
                    <div>
                        <h4 class="text-lg font-light text-gray-900 dark:text-white">PraluentÂ® (alirocumab)</h4>
                        <p class="text-xs text-gray-500 dark:text-gray-400">Sanofi/Regeneron - PCSK9 mAb</p>
                    </div>
                    <span class="px-3 py-1 text-xs font-medium bg-gradient-to-r from-green-100 to-emerald-100 dark:from-green-900/30 dark:to-emerald-900/30 text-green-700 dark:text-green-300 rounded-full">Aligned</span>
                </div>
                <div class="grid grid-cols-1 md:grid-cols-2 gap-4">
                    <div class="p-3 bg-blue-50 dark:bg-blue-900/20 rounded-lg border-l-4 border-blue-500">
                        <div class="flex items-center gap-2 mb-2">
                            <span>ðŸ‡ªðŸ‡º</span>
                            <span class="font-medium text-sm text-gray-900 dark:text-white">EMA Approval</span>
                        </div>
                        <div class="space-y-1 text-xs text-gray-600 dark:text-gray-400">
                            <p><strong class="text-gray-900 dark:text-white">Date:</strong> 2015</p>
                            <p><strong class="text-gray-900 dark:text-white">Label:</strong> Includes CV risk reduction</p>
                            <p><strong class="text-gray-900 dark:text-white">Pediatric:</strong> HeFH from age 8</p>
                        </div>
                    </div>
                    <div class="p-3 bg-red-50 dark:bg-red-900/20 rounded-lg border-l-4 border-red-500">
                        <div class="flex items-center gap-2 mb-2">
                            <span>ðŸ‡ºðŸ‡¸</span>
                            <span class="font-medium text-sm text-gray-900 dark:text-white">FDA Approval</span>
                        </div>
                        <div class="space-y-1 text-xs text-gray-600 dark:text-gray-400">
                            <p><strong class="text-gray-900 dark:text-white">Date:</strong> 2015</p>
                            <p><strong class="text-gray-900 dark:text-white">CV Outcomes:</strong> May 2019 - MI, stroke</p>
                            <p><strong class="text-gray-900 dark:text-white">Evidence:</strong> ODYSSEY OUTCOMES</p>
                        </div>
                    </div>
                </div>
                <div class="mt-3 p-2 bg-green-50 dark:bg-green-900/20 rounded border-l-4 border-green-500">
                    <p class="text-xs text-gray-700 dark:text-gray-300">
                        <strong>Key Divergence:</strong> Both approved simultaneously. FDA added CV outcomes 4 years post-approval. EMA includes broader pediatric indication.
                    </p>
                </div>
            </div>

            <!-- Bempedoic Acid -->
            <div class="mb-6 p-4 bg-white dark:bg-gray-800 rounded-lg hover:shadow-lg transition-shadow">
                <div class="flex items-start justify-between mb-4">
                    <div>
                        <h4 class="text-lg font-light text-gray-900 dark:text-white">Bempedoic Acid</h4>
                        <p class="text-xs text-gray-500 dark:text-gray-400">Esperion - Oral ACL Inhibitor</p>
                    </div>
                    <span class="px-3 py-1 text-xs font-medium bg-gradient-to-r from-green-100 to-emerald-100 dark:from-green-900/30 dark:to-emerald-900/30 text-green-700 dark:text-green-300 rounded-full">Synchronized 2024</span>
                </div>
                <div class="grid grid-cols-1 md:grid-cols-2 gap-4">
                    <div class="p-3 bg-blue-50 dark:bg-blue-900/20 rounded-lg border-l-4 border-blue-500">
                        <div class="flex items-center gap-2 mb-2">
                            <span>ðŸ‡ªðŸ‡º</span>
                            <span class="font-medium text-sm text-gray-900 dark:text-white">EMA (Nilemdo/Nustendi)</span>
                        </div>
                        <div class="space-y-1 text-xs text-gray-600 dark:text-gray-400">
                            <p><strong class="text-gray-900 dark:text-white">Initial:</strong> LDL-C lowering</p>
                            <p><strong class="text-gray-900 dark:text-white">March 2024:</strong> CHMP positive for CV risk</p>
                            <p><strong class="text-gray-900 dark:text-white">Note:</strong> Combination pill available</p>
                        </div>
                    </div>
                    <div class="p-3 bg-red-50 dark:bg-red-900/20 rounded-lg border-l-4 border-red-500">
                        <div class="flex items-center gap-2 mb-2">
                            <span>ðŸ‡ºðŸ‡¸</span>
                            <span class="font-medium text-sm text-gray-900 dark:text-white">FDA (Nexletol/Nexlizet)</span>
                        </div>
                        <div class="space-y-1 text-xs text-gray-600 dark:text-gray-400">
                            <p><strong class="text-gray-900 dark:text-white">2020:</strong> Approved for LDL-C</p>
                            <p><strong class="text-gray-900 dark:text-white">March 22, 2024:</strong> CV risk expansion</p>
                            <p><strong class="text-gray-900 dark:text-white">Products:</strong> Both formulations updated</p>
                        </div>
                    </div>
                </div>
                <div class="mt-3 p-2 bg-green-50 dark:bg-green-900/20 rounded border-l-4 border-green-500">
                    <p class="text-xs text-gray-700 dark:text-gray-300">
                        <strong>Key Divergence:</strong> Both agencies moved simultaneously in March 2024 following CLEAR Outcomes trial. Regulatory alignment achieved.
                    </p>
                </div>
            </div>

            <!-- Evinacumab -->
            <div class="p-4 bg-white dark:bg-gray-800 rounded-lg hover:shadow-lg transition-shadow">
                <div class="flex items-start justify-between mb-4">
                    <div>
                        <h4 class="text-lg font-light text-gray-900 dark:text-white">Evinacumab (EvkeezaÂ®)</h4>
                        <p class="text-xs text-gray-500 dark:text-gray-400">Regeneron/Ultragenyx - ANGPTL3 mAb for HoFH</p>
                    </div>
                    <span class="px-3 py-1 text-xs font-medium bg-gradient-to-r from-amber-100 to-orange-100 dark:from-amber-900/30 dark:to-orange-900/30 text-amber-700 dark:text-amber-300 rounded-full">Major Age Gap</span>
                </div>
                <div class="grid grid-cols-1 md:grid-cols-2 gap-4">
                    <div class="p-3 bg-blue-50 dark:bg-blue-900/20 rounded-lg border-l-4 border-blue-500">
                        <div class="flex items-center gap-2 mb-2">
                            <span>ðŸ‡ªðŸ‡º</span>
                            <span class="font-medium text-sm text-gray-900 dark:text-white">EMA Approval</span>
                        </div>
                        <div class="space-y-1 text-xs text-gray-600 dark:text-gray-400">
                            <p><strong class="text-gray-900 dark:text-white">Date:</strong> June 17, 2021</p>
                            <p><strong class="text-gray-900 dark:text-white">Age Range:</strong> <span class="px-2 py-0.5 bg-green-100 dark:bg-green-900/30 text-green-700 dark:text-green-300 rounded">â‰¥6 months</span></p>
                            <p><strong class="text-gray-900 dark:text-white">Population:</strong> All ages with HoFH</p>
                        </div>
                    </div>
                    <div class="p-3 bg-red-50 dark:bg-red-900/20 rounded-lg border-l-4 border-red-500">
                        <div class="flex items-center gap-2 mb-2">
                            <span>ðŸ‡ºðŸ‡¸</span>
                            <span class="font-medium text-sm text-gray-900 dark:text-white">FDA Approval</span>
                        </div>
                        <div class="space-y-1 text-xs text-gray-600 dark:text-gray-400">
                            <p><strong class="text-gray-900 dark:text-white">Date:</strong> February 11, 2021</p>
                            <p><strong class="text-gray-900 dark:text-white">Current Age:</strong> <span class="px-2 py-0.5 bg-amber-100 dark:bg-amber-900/30 text-amber-700 dark:text-amber-300 rounded">â‰¥5 years</span></p>
                            <p><strong class="text-gray-900 dark:text-white">Extension:</strong> March 2023 (was â‰¥12 years)</p>
                        </div>
                    </div>
                </div>
                <div class="mt-3 p-2 bg-amber-50 dark:bg-amber-900/20 rounded border-l-4 border-amber-500">
                    <p class="text-xs text-gray-700 dark:text-gray-300">
                        <strong>Key Divergence:</strong> Largest age gap in the class. EMA shows greater willingness to approve for very young patients in ultra-rare disease (6 months vs 5 years).
                    </p>
                </div>
            </div>
        </div>

        <!-- Pipeline Comparison Table -->
        <div class="glass rounded-2xl p-6 border border-gray-200 dark:border-gray-700">
            <h3 class="mb-4 text-xl font-light text-gray-900 dark:text-white">Pipeline & Emerging Therapies Status</h3>
            <div class="overflow-x-auto">
                <table class="w-full">
                    <thead>
                        <tr class="bg-gray-50 dark:bg-gray-800">
                            <th class="px-4 py-3 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Drug/Company</th>
                            <th class="px-4 py-3 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Mechanism</th>
                            <th class="px-4 py-3 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">US Status</th>
                            <th class="px-4 py-3 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">EU Status</th>
                        </tr>
                    </thead>
                    <tbody class="divide-y divide-gray-200 dark:divide-gray-700">
                        <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                            <td class="px-4 py-3 text-sm text-gray-900 dark:text-white"><strong>LIB003</strong><br>LIB Therapeutics</td>
                            <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Monthly PCSK9 adnectin</td>
                            <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">BLA accepted<br>PDUFA: Dec 12, 2025</td>
                            <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">MAA expected Q1 2026</td>
                        </tr>
                        <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                            <td class="px-4 py-3 text-sm text-gray-900 dark:text-white"><strong>MK-0616</strong><br>Merck</td>
                            <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Oral PCSK9 inhibitor</td>
                            <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Phase 3 ongoing</td>
                            <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Phase 3 ongoing</td>
                        </tr>
                        <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                            <td class="px-4 py-3 text-sm text-gray-900 dark:text-white"><strong>AZD0780</strong><br>AstraZeneca</td>
                            <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Oral PCSK9 inhibitor</td>
                            <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Phase 2b complete</td>
                            <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Phase 2b complete</td>
                        </tr>
                        <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                            <td class="px-4 py-3 text-sm text-gray-900 dark:text-white"><strong>VERVE-101</strong><br>Eli Lilly</td>
                            <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Gene editing</td>
                            <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Hold lifted Oct 2023</td>
                            <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Phase 1 ongoing</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>
    </div>
</div>
<div class="tab-content hidden" id="compliance">
    <div class="max-w-7xl mx-auto px-4 sm:px-6 lg:px-8 py-8">
        <!-- Hero Section -->
        <div class="glass rounded-2xl p-8 mb-8 border border-gray-200 dark:border-gray-700">
            <h1 class="text-3xl font-light mb-2 text-gray-900 dark:text-white">
                Compliance History & Regulatory Analysis
            </h1>
            <p class="text-sm text-gray-600 dark:text-gray-400">
                Minimal regulatory friction, mostly CMC-related issues
            </p>
        </div>

        <!-- Executive Summary -->
        <div class="glass rounded-2xl p-8 mb-8 border border-gray-200 dark:border-gray-700">
            <h2 class="flex items-center gap-2 mb-6 text-xl font-light text-gray-900 dark:text-white">
                <span>ðŸŽ¯</span> Compliance Overview
            </h2>
            <div class="grid grid-cols-1 lg:grid-cols-2 gap-8">
                <div>
                    <h3 class="mb-4 text-lg font-light text-gray-800 dark:text-gray-200">Key Compliance Patterns</h3>
                    <ul class="space-y-3">
                        <li class="text-sm text-gray-600 dark:text-gray-400 animate-slide-in">
                            <strong class="text-gray-900 dark:text-white">Manufacturing dominates delays</strong> - 3 holds/CRLs all CMC-related, not clinical
                        </li>
                        <li class="text-sm text-gray-600 dark:text-gray-400 animate-slide-in stagger-1">
                            <strong class="text-gray-900 dark:text-white">No OPDP enforcement</strong> - Zero warning letters for PCSK9 class to date
                        </li>
                        <li class="text-sm text-gray-600 dark:text-gray-400 animate-slide-in stagger-2">
                            <strong class="text-gray-900 dark:text-white">COVID exposed vulnerabilities</strong> - Third-party facility access became critical
                        </li>
                        <li class="text-sm text-gray-600 dark:text-gray-400 animate-slide-in stagger-3">
                            <strong class="text-gray-900 dark:text-white">Novel modalities scrutinized</strong> - Gene editing faced 11-month hold
                        </li>
                    </ul>
                </div>
                <div>
                    <h3 class="mb-4 text-lg font-light text-gray-800 dark:text-gray-200">Regulatory Success Factors</h3>
                    <ul class="space-y-3">
                        <li class="text-sm text-gray-600 dark:text-gray-400 animate-slide-in stagger-4">
                            <strong class="text-gray-900 dark:text-white">Clean safety profiles</strong> - No clinical safety-driven CRLs
                        </li>
                        <li class="text-sm text-gray-600 dark:text-gray-400 animate-slide-in stagger-5">
                            <strong class="text-gray-900 dark:text-white">Smooth label expansions</strong> - CV outcomes added without friction
                        </li>
                        <li class="text-sm text-gray-600 dark:text-gray-400 animate-slide-in" style="animation-delay: 0.6s;">
                            <strong class="text-gray-900 dark:text-white">8+ years post-market success</strong> - Repatha/Praluent proven track records
                        </li>
                        <li class="text-sm text-gray-600 dark:text-gray-400 animate-slide-in" style="animation-delay: 0.7s;">
                            <strong class="text-gray-900 dark:text-white">Established tech advantage</strong> - mAbs and small molecules face less scrutiny
                        </li>
                    </ul>
                </div>
            </div>
            <div class="mt-6 p-4 bg-gradient-to-r from-indigo-50 to-purple-50 dark:from-indigo-900/20 dark:to-purple-900/20 rounded-lg border-l-4 border-indigo-500">
                <p class="text-sm text-gray-700 dark:text-gray-300">
                    <span class="text-lg mr-2">ðŸ’¡</span>
                    <strong>Key Insight:</strong> The cholesterol therapy space shows remarkably clean compliance history with regulatory issues limited to manufacturing/CMC rather than safety or efficacy. Third-party manufacturing readiness and novel modality safety data are the primary regulatory risk factors.
                </p>
            </div>
        </div>

        <!-- Compliance Timeline -->
        <div class="glass rounded-2xl p-6 mb-8 border border-gray-200 dark:border-gray-700">
            <h3 class="mb-6 text-xl font-light text-gray-900 dark:text-white">Regulatory Timeline</h3>
            
            <div class="relative pl-8">
                <!-- Timeline line -->
                <div class="absolute left-3 top-0 bottom-0 w-0.5 bg-gradient-to-b from-transparent via-indigo-300 dark:via-indigo-600 to-transparent"></div>
                
                <!-- Timeline items -->
                <div class="relative mb-8">
                    <div class="absolute -left-5 w-4 h-4 bg-red-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                    <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md hover:shadow-lg transition-shadow">
                        <div class="text-xs font-medium text-indigo-600 dark:text-indigo-400 mb-1">DECEMBER 2020</div>
                        <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Inclisiran Complete Response Letter</div>
                        <div class="text-xs text-gray-600 dark:text-gray-400 space-y-1">
                            <p><strong class="text-gray-900 dark:text-white">Issue:</strong> Third-party manufacturing facility inspection</p>
                            <p><strong class="text-gray-900 dark:text-white">Context:</strong> COVID-19 restricted FDA access</p>
                            <p><strong class="text-gray-900 dark:text-white">Important:</strong> No clinical/safety/efficacy concerns</p>
                        </div>
                    </div>
                </div>

                <div class="relative mb-8">
                    <div class="absolute -left-5 w-4 h-4 bg-green-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                    <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md hover:shadow-lg transition-shadow">
                        <div class="text-xs font-medium text-indigo-600 dark:text-indigo-400 mb-1">DECEMBER 21, 2021</div>
                        <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Inclisiran CRL Resolution</div>
                        <div class="text-xs text-gray-600 dark:text-gray-400 space-y-1">
                            <p><strong class="text-gray-900 dark:text-white">Resolution:</strong> Facility inspection completed</p>
                            <p><strong class="text-gray-900 dark:text-white">Outcome:</strong> Full FDA approval granted</p>
                        </div>
                    </div>
                </div>

                <div class="relative mb-8">
                    <div class="absolute -left-5 w-4 h-4 bg-red-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                    <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md hover:shadow-lg transition-shadow">
                        <div class="text-xs font-medium text-indigo-600 dark:text-indigo-400 mb-1">NOVEMBER 2022</div>
                        <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">VERVE-101 Clinical Hold</div>
                        <div class="text-xs text-gray-600 dark:text-gray-400 space-y-1">
                            <p><strong class="text-gray-900 dark:text-white">Product:</strong> PCSK9 gene editor</p>
                            <p><strong class="text-gray-900 dark:text-white">Reason:</strong> First-in-human safety review</p>
                            <p><strong class="text-gray-900 dark:text-white">Requirements:</strong> Additional safety data</p>
                        </div>
                    </div>
                </div>

                <div class="relative">
                    <div class="absolute -left-5 w-4 h-4 bg-green-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                    <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md hover:shadow-lg transition-shadow">
                        <div class="text-xs font-medium text-indigo-600 dark:text-indigo-400 mb-1">OCTOBER 2023</div>
                        <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">VERVE-101 Hold Lifted</div>
                        <div class="text-xs text-gray-600 dark:text-gray-400 space-y-1">
                            <p><strong class="text-gray-900 dark:text-white">Resolution:</strong> FDA reviewed additional materials</p>
                            <p><strong class="text-gray-900 dark:text-white">Outcome:</strong> US studies permitted to continue</p>
                            <p><strong class="text-gray-900 dark:text-white">Note:</strong> Eli Lilly acquired assets July 2025</p>
                        </div>
                    </div>
                </div>
            </div>
        </div>

        <!-- Company-by-Company Analysis -->
        <div class="glass rounded-2xl p-6 mb-8 border border-gray-200 dark:border-gray-700">
            <h3 class="mb-6 text-xl font-light text-gray-900 dark:text-white">Detailed Compliance Analysis by Company</h3>
            
            <!-- Novartis -->
            <div class="mb-6 p-4 bg-white dark:bg-gray-800 rounded-lg hover:shadow-lg transition-shadow">
                <div class="flex items-start justify-between mb-4">
                    <div>
                        <h4 class="text-lg font-light text-gray-900 dark:text-white">Novartis (Inclisiran)</h4>
                        <p class="text-xs text-gray-500 dark:text-gray-400">siRNA therapy</p>
                    </div>
                    <span class="px-3 py-1 text-xs font-medium bg-gradient-to-r from-amber-100 to-orange-100 dark:from-amber-900/30 dark:to-orange-900/30 text-amber-700 dark:text-amber-300 rounded-full">CRL - CMC Issue</span>
                </div>
                
                <div class="space-y-4">
                    <div>
                        <h5 class="text-sm font-medium text-gray-900 dark:text-white mb-2">Complete Response Letter Details (December 2020)</h5>
                        <ul class="space-y-2 text-xs text-gray-600 dark:text-gray-400">
                            <li>â€¢ <strong class="text-gray-900 dark:text-white">Primary Issue:</strong> Inability to conduct on-site inspection at third-party manufacturing facility</li>
                            <li>â€¢ <strong class="text-gray-900 dark:text-white">COVID Impact:</strong> Travel restrictions prevented FDA inspectors from accessing facility</li>
                            <li>â€¢ <strong class="text-gray-900 dark:text-white">FDA Statement:</strong> "No concerns related to clinical efficacy or safety"</li>
                            <li>â€¢ <strong class="text-gray-900 dark:text-white">Resolution Timeline:</strong> 12 months from CRL to approval</li>
                            <li>â€¢ <strong class="text-gray-900 dark:text-white">Key Learning:</strong> Third-party CMC readiness as critical as internal facilities</li>
                        </ul>
                    </div>
                    
                    <div>
                        <h5 class="text-sm font-medium text-gray-900 dark:text-white mb-2">Post-Approval Compliance</h5>
                        <ul class="space-y-2 text-xs text-gray-600 dark:text-gray-400">
                            <li>â€¢ No OPDP warning or untitled letters issued</li>
                            <li>â€¢ Successful label expansion in 2023 without friction</li>
                            <li>â€¢ NHS England population health deal demonstrates system-level acceptance</li>
                        </ul>
                    </div>
                </div>
            </div>

            <!-- Amgen -->
            <div class="mb-6 p-4 bg-white dark:bg-gray-800 rounded-lg hover:shadow-lg transition-shadow">
                <div class="flex items-start justify-between mb-4">
                    <div>
                        <h4 class="text-lg font-light text-gray-900 dark:text-white">Amgen (Repatha)</h4>
                        <p class="text-xs text-gray-500 dark:text-gray-400">PCSK9 mAb</p>
                    </div>
                    <span class="px-3 py-1 text-xs font-medium bg-gradient-to-r from-green-100 to-emerald-100 dark:from-green-900/30 dark:to-emerald-900/30 text-green-700 dark:text-green-300 rounded-full">Clean Record</span>
                </div>
                
                <ul class="space-y-2 text-xs text-gray-600 dark:text-gray-400">
                    <li>â€¢ <strong class="text-gray-900 dark:text-white">Approval Process:</strong> No CRLs during original BLA or subsequent supplements</li>
                    <li>â€¢ <strong class="text-gray-900 dark:text-white">OPDP History:</strong> No warning or untitled letters specific to Repatha identified</li>
                    <li>â€¢ <strong class="text-gray-900 dark:text-white">Label Updates:</strong> Smooth addition of CV outcomes data (2017) without regulatory friction</li>
                    <li>â€¢ <strong class="text-gray-900 dark:text-white">Manufacturing:</strong> No facility inspection issues reported</li>
                    <li>â€¢ <strong class="text-gray-900 dark:text-white">Post-Market:</strong> 8+ years without significant compliance events</li>
                </ul>
            </div>

            <!-- Sanofi/Regeneron -->
            <div class="mb-6 p-4 bg-white dark:bg-gray-800 rounded-lg hover:shadow-lg transition-shadow">
                <div class="flex items-start justify-between mb-4">
                    <div>
                        <h4 class="text-lg font-light text-gray-900 dark:text-white">Sanofi/Regeneron (Praluent)</h4>
                        <p class="text-xs text-gray-500 dark:text-gray-400">PCSK9 mAb</p>
                    </div>
                    <span class="px-3 py-1 text-xs font-medium bg-gradient-to-r from-green-100 to-emerald-100 dark:from-green-900/30 dark:to-emerald-900/30 text-green-700 dark:text-green-300 rounded-full">Clean Record</span>
                </div>
                
                <ul class="space-y-2 text-xs text-gray-600 dark:text-gray-400">
                    <li>â€¢ <strong class="text-gray-900 dark:text-white">Regulatory History:</strong> Clean approval pathway in both EMA and FDA (2015)</li>
                    <li>â€¢ <strong class="text-gray-900 dark:text-white">OPDP Status:</strong> No enforcement actions identified</li>
                    <li>â€¢ <strong class="text-gray-900 dark:text-white">CV Outcomes Addition:</strong> FDA label update (May 2019) proceeded without issues</li>
                    <li>â€¢ <strong class="text-gray-900 dark:text-white">Manufacturing:</strong> No reported CMC-related delays or holds</li>
                    <li>â€¢ <strong class="text-gray-900 dark:text-white">Patent Litigation:</strong> Resolved Amgen patent dispute (2019) - business not regulatory issue</li>
                </ul>
            </div>

            <!-- Esperion -->
            <div class="mb-6 p-4 bg-white dark:bg-gray-800 rounded-lg hover:shadow-lg transition-shadow">
                <div class="flex items-start justify-between mb-4">
                    <div>
                        <h4 class="text-lg font-light text-gray-900 dark:text-white">Esperion (Bempedoic Acid)</h4>
                        <p class="text-xs text-gray-500 dark:text-gray-400">Oral ACL Inhibitor</p>
                    </div>
                    <span class="px-3 py-1 text-xs font-medium bg-gradient-to-r from-green-100 to-emerald-100 dark:from-green-900/30 dark:to-emerald-900/30 text-green-700 dark:text-green-300 rounded-full">Clean Record</span>
                </div>
                
                <ul class="space-y-2 text-xs text-gray-600 dark:text-gray-400">
                    <li>â€¢ <strong class="text-gray-900 dark:text-white">Approval:</strong> No CRLs identified for Nexletol or Nexlizet</li>
                    <li>â€¢ <strong class="text-gray-900 dark:text-white">OPDP:</strong> No direct enforcement actions</li>
                    <li>â€¢ <strong class="text-gray-900 dark:text-white">CV Label Update:</strong> March 2024 expansion proceeded smoothly in both US and EU</li>
                    <li>â€¢ <strong class="text-gray-900 dark:text-white">Class Relevance:</strong> OPDP's 2022 Roszet letter highlights scrutiny on LDL-C promotional claims</li>
                </ul>
            </div>

            <!-- Verve/Eli Lilly -->
            <div class="p-4 bg-white dark:bg-gray-800 rounded-lg hover:shadow-lg transition-shadow">
                <div class="flex items-start justify-between mb-4">
                    <div>
                        <h4 class="text-lg font-light text-gray-900 dark:text-white">Verve/Eli Lilly (Gene Editing)</h4>
                        <p class="text-xs text-gray-500 dark:text-gray-400">PCSK9 base editing</p>
                    </div>
                    <span class="px-3 py-1 text-xs font-medium bg-gradient-to-r from-amber-100 to-orange-100 dark:from-amber-900/30 dark:to-orange-900/30 text-amber-700 dark:text-amber-300 rounded-full">Clinical Hold</span>
                </div>
                
                <div class="space-y-4">
                    <div>
                        <h5 class="text-sm font-medium text-gray-900 dark:text-white mb-2">Clinical Hold Analysis (November 2022 - October 2023)</h5>
                        <div class="grid grid-cols-1 md:grid-cols-2 gap-4">
                            <div>
                                <h6 class="text-xs font-medium text-gray-700 dark:text-gray-300 mb-2">FDA Concerns:</h6>
                                <ul class="space-y-1 text-xs text-gray-600 dark:text-gray-400">
                                    <li>â€¢ Off-target editing potential</li>
                                    <li>â€¢ Long-term safety of permanent modification</li>
                                    <li>â€¢ Dose selection for first-in-human</li>
                                    <li>â€¢ Patient selection criteria</li>
                                </ul>
                            </div>
                            <div>
                                <h6 class="text-xs font-medium text-gray-700 dark:text-gray-300 mb-2">Resolution Requirements:</h6>
                                <ul class="space-y-1 text-xs text-gray-600 dark:text-gray-400">
                                    <li>â€¢ Additional preclinical safety studies</li>
                                    <li>â€¢ Enhanced off-target analysis</li>
                                    <li>â€¢ Revised trial design</li>
                                    <li>â€¢ Updated informed consent</li>
                                </ul>
                            </div>
                        </div>
                    </div>
                    
                    <div class="p-3 bg-amber-50 dark:bg-amber-900/20 rounded border-l-4 border-amber-500">
                        <p class="text-xs text-gray-700 dark:text-gray-300">
                            <strong>Outcome:</strong> Hold lifted after 11 months with pathway established. Set precedent for gene editing regulatory requirements.
                        </p>
                    </div>
                </div>
            </div>
        </div>

        <!-- Key Compliance Lessons -->
        <div class="grid grid-cols-1 lg:grid-cols-2 gap-6 mb-8">
            <!-- Manufacturing & CMC -->
            <div class="glass rounded-xl p-6 border border-gray-200 dark:border-gray-700">
                <h3 class="flex items-center gap-2 mb-4 text-lg font-light text-gray-900 dark:text-white">
                    <span>âš™ï¸</span> Manufacturing & CMC Readiness
                </h3>
                <p class="text-xs text-gray-600 dark:text-gray-400 mb-3">
                    The inclisiran CRL demonstrates that manufacturing can be rate-limiting:
                </p>
                <ul class="space-y-2 text-xs text-gray-600 dark:text-gray-400">
                    <li>â€¢ <strong class="text-gray-900 dark:text-white">Third-party readiness critical:</strong> As important as sponsor facilities</li>
                    <li>â€¢ <strong class="text-gray-900 dark:text-white">COVID exposed vulnerabilities:</strong> Global manufacturing network gaps</li>
                    <li>â€¢ <strong class="text-gray-900 dark:text-white">FDA strictness maintained:</strong> No exceptions for external circumstances</li>
                    <li>â€¢ <strong class="text-gray-900 dark:text-white">Multiple sites advised:</strong> Mitigate single-point failures</li>
                </ul>
            </div>

            <!-- Promotional Compliance -->
            <div class="glass rounded-xl p-6 border border-gray-200 dark:border-gray-700">
                <h3 class="flex items-center gap-2 mb-4 text-lg font-light text-gray-900 dark:text-white">
                    <span>ðŸ“¢</span> Promotional Compliance Environment
                </h3>
                <p class="text-xs text-gray-600 dark:text-gray-400 mb-3">
                    While no PCSK9 inhibitors have received OPDP letters:
                </p>
                <ul class="space-y-2 text-xs text-gray-600 dark:text-gray-400">
                    <li>â€¢ <strong class="text-gray-900 dark:text-white">Composite endpoints scrutinized:</strong> FDA reviews claims carefully</li>
                    <li>â€¢ <strong class="text-gray-900 dark:text-white">Analysis methods matter:</strong> mITT and LOCF need clear presentation</li>
                    <li>â€¢ <strong class="text-gray-900 dark:text-white">Multiplicity adjustments:</strong> Must be clearly disclosed</li>
                    <li>â€¢ <strong class="text-gray-900 dark:text-white">LDL-C claims precision:</strong> Must align with trial designs</li>
                </ul>
            </div>
        </div>

        <!-- Novel Modality Considerations -->
        <div class="glass rounded-2xl p-6 border border-gray-200 dark:border-gray-700">
            <h3 class="mb-4 text-xl font-light text-gray-900 dark:text-white">Novel Modality Regulatory Considerations</h3>
            <div class="grid grid-cols-1 md:grid-cols-2 gap-6">
                <div class="p-4 bg-gradient-to-r from-green-50 to-emerald-50 dark:from-green-900/20 dark:to-emerald-900/20 rounded-lg border-l-4 border-green-500">
                    <h4 class="text-sm font-medium text-gray-900 dark:text-white mb-3">âœ… Established Technologies (Lower Friction)</h4>
                    <ul class="space-y-2 text-xs text-gray-600 dark:text-gray-400">
                        <li>â€¢ Small molecules (statins, bempedoic acid)</li>
                        <li>â€¢ Monoclonal antibodies (Repatha, Praluent)</li>
                        <li>â€¢ siRNA with established delivery (inclisiran)</li>
                    </ul>
                </div>
                <div class="p-4 bg-gradient-to-r from-amber-50 to-orange-50 dark:from-amber-900/20 dark:to-orange-900/20 rounded-lg border-l-4 border-amber-500">
                    <h4 class="text-sm font-medium text-gray-900 dark:text-white mb-3">âš ï¸ Novel Technologies (Higher Scrutiny)</h4>
                    <ul class="space-y-2 text-xs text-gray-600 dark:text-gray-400">
                        <li>â€¢ In vivo gene editing (VERVE-101)</li>
                        <li>â€¢ Base editing approaches</li>
                        <li>â€¢ Permanent genetic modifications</li>
                    </ul>
                </div>
            </div>
        </div>
    </div>
</div>
        <!-- Competitors Tab -->
        <div class="tab-content hidden" id="approved">
            <div class="max-w-7xl mx-auto px-4 sm:px-6 lg:px-8 py-8">
                <!-- Header Section -->
                <div class="glass rounded-2xl p-6 mb-6 border border-gray-200 dark:border-gray-700">
                    <h2 class="text-2xl font-light mb-4 text-gray-900 dark:text-white flex items-center gap-3">
                        <svg class="w-6 h-6" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2">
                            <path d="M9 11H3V21H9V11Z M15 3H9V21H15V3Z M21 7H15V21H21V7Z" stroke-linecap="round" stroke-linejoin="round"/>
                        </svg>
                        Competitive Landscape Analysis
                    </h2>
                    
                    <!-- Filter Controls -->
                    <div class="flex flex-wrap gap-2">
                        <button class="filter-btn px-4 py-2 rounded-lg text-sm font-medium transition-all bg-indigo-600 text-white" onclick="filterTable('all', event)">
                            All Therapies
                        </button>
                        <button class="filter-btn px-4 py-2 rounded-lg text-sm font-medium transition-all bg-gray-100 dark:bg-gray-800 text-gray-700 dark:text-gray-300 hover:bg-gray-200 dark:hover:bg-gray-700" onclick="filterTable('approved', event)">
                            Approved
                        </button>
                        <button class="filter-btn px-4 py-2 rounded-lg text-sm font-medium transition-all bg-gray-100 dark:bg-gray-800 text-gray-700 dark:text-gray-300 hover:bg-gray-200 dark:hover:bg-gray-700" onclick="filterTable('pipeline', event)">
                            Pipeline
                        </button>
                        <button class="filter-btn px-4 py-2 rounded-lg text-sm font-medium transition-all bg-gray-100 dark:bg-gray-800 text-gray-700 dark:text-gray-300 hover:bg-gray-200 dark:hover:bg-gray-700" onclick="filterTable('pcsk9', event)">
                            PCSK9 Inhibitors
                        </button>
                        <button class="filter-btn px-4 py-2 rounded-lg text-sm font-medium transition-all bg-gray-100 dark:bg-gray-800 text-gray-700 dark:text-gray-300 hover:bg-gray-200 dark:hover:bg-gray-700" onclick="filterTable('other', event)">
                            Other Mechanisms
                        </button>
                    </div>
                </div>

                <!-- Table -->
                <div class="glass rounded-2xl overflow-hidden border border-gray-200 dark:border-gray-700">
                    <div class="overflow-x-auto">
                        <table class="w-full">
                            <thead class="bg-gray-50 dark:bg-gray-800 border-b border-gray-200 dark:border-gray-700">
                                <tr>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Drug / Company</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Status</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Dosing</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Efficacy</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Recent Events</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Actions</th>
                                </tr>
                            </thead>
                            <tbody class="divide-y divide-gray-200 dark:divide-gray-700">
                                <!-- Repatha -->
                                <tr class="approved pcsk9 hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <div class="text-base font-medium text-gray-900 dark:text-white">RepathaÂ® (evolocumab)</div>
                                            <div class="text-sm text-indigo-600 dark:text-indigo-400">Amgen</div>
                                            <div class="inline-block px-2 py-1 text-xs bg-gray-100 dark:bg-gray-800 text-gray-700 dark:text-gray-300 rounded">PCSK9 Monoclonal Antibody</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-green-100 dark:bg-green-900/30 text-green-800 dark:text-green-400">
                                                âœ“ Approved
                                            </span>
                                            <div class="text-xs text-gray-500 dark:text-gray-400">FDA/EMA 2015</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <div class="text-sm text-gray-900 dark:text-white">140 mg Q2W or 420 mg monthly</div>
                                            <div class="text-xs text-gray-500 dark:text-gray-400">SC â€¢ 12-26 injections/year</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-2">
                                            <div class="w-full bg-gray-200 dark:bg-gray-700 rounded-full h-2">
                                                <div class="bg-gradient-to-r from-indigo-500 to-purple-500 h-2 rounded-full text-xs text-white text-center" style="width: 60%"></div>
                                            </div>
                                            <div class="text-xs text-gray-600 dark:text-gray-400">15% MACE reduction</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <div class="flex items-center gap-2 text-xs text-gray-600 dark:text-gray-400">
                                                <span class="text-green-600 dark:text-green-400">$</span>
                                                <span>Price cut 60% post-outcomes</span>
                                            </div>
                                            <div class="flex items-center gap-2 text-xs text-gray-600 dark:text-gray-400">
                                                <span class="text-green-600 dark:text-green-400">âœ“</span>
                                                <span>8+ years safety record</span>
                                            </div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-2">
                                            <a href="repatha.html" class="inline-flex items-center px-3 py-1.5 text-xs font-medium rounded-lg bg-gradient-to-r from-indigo-600 to-purple-600 text-white hover:from-indigo-700 hover:to-purple-700 transition-all">
                                                View Details
                                            </a>
                                            <a href="https://leaf.intelligence/search?q=evolocumab" target="_blank" class="hidden inline-flex items-center px-3 py-1.5 text-xs font-medium rounded-lg border border-gray-300 dark:border-gray-600 text-gray-700 dark:text-gray-300 hover:bg-gray-50 dark:hover:bg-gray-800 transition-all">
                                                Leaf Intel
                                            </a>
                                        </div>
                                    </td>
                                </tr>

                                <!-- Praluent -->
                                <tr class="approved pcsk9 hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <div class="text-base font-medium text-gray-900 dark:text-white">PraluentÂ® (alirocumab)</div>
                                            <div class="text-sm text-indigo-600 dark:text-indigo-400">Sanofi/Regeneron</div>
                                            <div class="inline-block px-2 py-1 text-xs bg-gray-100 dark:bg-gray-800 text-gray-700 dark:text-gray-300 rounded">PCSK9 Monoclonal Antibody</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-green-100 dark:bg-green-900/30 text-green-800 dark:text-green-400">
                                                âœ“ Approved
                                            </span>
                                            <div class="text-xs text-gray-500 dark:text-gray-400">FDA/EMA 2015</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <div class="text-sm text-gray-900 dark:text-white">75-150 mg Q2W or 300 mg monthly</div>
                                            <div class="text-xs text-gray-500 dark:text-gray-400">SC â€¢ 12-26 injections/year</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-2">
                                            <div class="w-full bg-gray-200 dark:bg-gray-700 rounded-full h-2">
                                                <div class="bg-gradient-to-r from-indigo-500 to-purple-500 h-2 rounded-full text-xs text-white text-center" style="width: 55%"></div>
                                            </div>
                                            <div class="text-xs text-gray-600 dark:text-gray-400">15% MACE, 15% mortalityâ†“</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <div class="flex items-center gap-2 text-xs text-gray-600 dark:text-gray-400">
                                                <span class="text-amber-600 dark:text-amber-400">â˜…</span>
                                                <span>Only PCSK9i w/ mortality</span>
                                            </div>
                                            <div class="flex items-center gap-2 text-xs text-gray-600 dark:text-gray-400">
                                                <span class="text-green-600 dark:text-green-400">âœ“</span>
                                                <span>Patent resolved</span>
                                            </div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-2">
                                            <a href="praluent.html" class="inline-flex items-center px-3 py-1.5 text-xs font-medium rounded-lg bg-gradient-to-r from-indigo-600 to-purple-600 text-white hover:from-indigo-700 hover:to-purple-700 transition-all">
                                                View Details
                                            </a>
                                            <a href="https://leaf.intelligence/search?q=alirocumab" target="_blank" class="hidden inline-flex items-center px-3 py-1.5 text-xs font-medium rounded-lg border border-gray-300 dark:border-gray-600 text-gray-700 dark:text-gray-300 hover:bg-gray-50 dark:hover:bg-gray-800 transition-all">
                                                Leaf Intel
                                            </a>
                                        </div>
                                    </td>
                                </tr>

                                <!-- Ebronucimab -->
                                <tr class="approved pcsk9 hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <div class="text-base font-medium text-gray-900 dark:text-white">Ebronucimab (AK102)</div>
                                            <div class="text-sm text-indigo-600 dark:text-indigo-400">Akeso Inc.</div>
                                            <div class="inline-block px-2 py-1 text-xs bg-gray-100 dark:bg-gray-800 text-gray-700 dark:text-gray-300 rounded">PCSK9 Monoclonal Antibody</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-green-100 dark:bg-green-900/30 text-green-800 dark:text-green-400">
                                                âœ“ Approved
                                            </span>
                                            <div class="text-xs text-gray-500 dark:text-gray-400">China NMPA 2024</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <div class="text-sm text-gray-900 dark:text-white">Q2W, Q4W, or Q6W</div>
                                            <div class="text-xs text-gray-500 dark:text-gray-400">SC â€¢ 8-26 injections/year</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-2">
                                            <div class="w-full bg-gray-200 dark:bg-gray-700 rounded-full h-2">
                                                <div class="bg-gradient-to-r from-indigo-500 to-purple-500 h-2 rounded-full text-xs text-white text-center" style="width: 65%"></div>
                                            </div>
                                            <div class="text-xs text-gray-600 dark:text-gray-400">CV outcomes pending</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <div class="flex items-center gap-2 text-xs text-gray-600 dark:text-gray-400">
                                                <span class="text-red-600 dark:text-red-400">CN</span>
                                                <span>China-only approval</span>
                                            </div>
                                            <div class="flex items-center gap-2 text-xs text-gray-600 dark:text-gray-400">
                                                <span class="text-indigo-600 dark:text-indigo-400">6W</span>
                                                <span>Q6W dosing advantage</span>
                                            </div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-2">
                                            <a href="ebronucimab.html" class="inline-flex items-center px-3 py-1.5 text-xs font-medium rounded-lg bg-gradient-to-r from-indigo-600 to-purple-600 text-white hover:from-indigo-700 hover:to-purple-700 transition-all">
                                                View Details
                                            </a>
                                            <a href="https://leaf.intelligence/search?q=ebronucimab" target="_blank" class="hidden inline-flex items-center px-3 py-1.5 text-xs font-medium rounded-lg border border-gray-300 dark:border-gray-600 text-gray-700 dark:text-gray-300 hover:bg-gray-50 dark:hover:bg-gray-800 transition-all">
                                                Leaf Intel
                                            </a>
                                        </div>
                                    </td>
                                </tr>

                                <!-- Bempedoic Acid -->
                                <tr class="approved other hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <div class="text-base font-medium text-gray-900 dark:text-white">NexletolÂ® (bempedoic acid)</div>
                                            <div class="text-sm text-indigo-600 dark:text-indigo-400">Esperion Therapeutics</div>
                                         <div class="inline-block px-2 py-1 text-xs bg-gray-100 dark:bg-gray-800 text-gray-700 dark:text-gray-300 rounded">ACL Inhibitor</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-green-100 dark:bg-green-900/30 text-green-800 dark:text-green-400">
                                                âœ“ Approved
                                            </span>
                                            <div class="text-xs text-gray-500 dark:text-gray-400">FDA/EMA 2020</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <div class="text-sm text-gray-900 dark:text-white">180 mg oral once daily</div>
                                            <div class="text-xs text-gray-500 dark:text-gray-400">~$400/month (US)</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-2">
                                            <div class="w-full bg-gray-200 dark:bg-gray-700 rounded-full h-2">
                                                <div class="bg-gradient-to-r from-indigo-500 to-purple-500 h-2 rounded-full text-xs text-white text-center" style="width: 22%"></div>
                                            </div>
                                            <div class="text-xs text-gray-600 dark:text-gray-400">13% MACE, 23% MIâ†“</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <div class="flex items-center gap-2 text-xs text-gray-600 dark:text-gray-400">
                                                <span class="text-blue-600 dark:text-blue-400">Rx</span>
                                                <span>Statin-intolerant pts</span>
                                            </div>
                                            <div class="flex items-center gap-2 text-xs text-gray-600 dark:text-gray-400">
                                                <span class="text-green-600 dark:text-green-400">âœ“</span>
                                                <span>CLEAR positive</span>
                                            </div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-2">
                                            <a href="other.html" class="inline-flex items-center px-3 py-1.5 text-xs font-medium rounded-lg bg-gradient-to-r from-indigo-600 to-purple-600 text-white hover:from-indigo-700 hover:to-purple-700 transition-all">
                                                View Details
                                            </a>
                                            <a href="https://leaf.intelligence/search?q=bempedoic+acid" target="_blank" class=" hidden inline-flex items-center px-3 py-1.5 text-xs font-medium rounded-lg border border-gray-300 dark:border-gray-600 text-gray-700 dark:text-gray-300 hover:bg-gray-50 dark:hover:bg-gray-800 transition-all">
                                                Leaf Intel
                                            </a>
                                        </div>
                                    </td>
                                </tr>

                                <!-- Ezetimibe -->
                                <tr class="approved other hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <div class="text-base font-medium text-gray-900 dark:text-white">Ezetimibe (ZetiaÂ®)</div>
                                            <div class="text-sm text-indigo-600 dark:text-indigo-400">Generic (Originally Merck)</div>
                                            <div class="inline-block px-2 py-1 text-xs bg-gray-100 dark:bg-gray-800 text-gray-700 dark:text-gray-300 rounded">Cholesterol Absorption Inhibitor</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-green-100 dark:bg-green-900/30 text-green-800 dark:text-green-400">
                                                âœ“ Approved
                                            </span>
                                            <div class="text-xs text-gray-500 dark:text-gray-400">FDA 2002 (Generic)</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <div class="text-sm text-gray-900 dark:text-white">10 mg oral once daily</div>
                                            <div class="text-xs text-gray-500 dark:text-gray-400">~$10-20/month (generic)</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-2">
                                            <div class="w-full bg-gray-200 dark:bg-gray-700 rounded-full h-2">
                                                <div class="bg-gradient-to-r from-indigo-500 to-purple-500 h-2 rounded-full text-xs text-white text-center" style="width: 20%"></div>
                                            </div>
                                            <div class="text-xs text-gray-600 dark:text-gray-400">6-7% MACEâ†“</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <div class="flex items-center gap-2 text-xs text-gray-600 dark:text-gray-400">
                                                <span class="text-blue-600 dark:text-blue-400">2</span>
                                                <span>Standard 2nd-line</span>
                                            </div>
                                            <div class="flex items-center gap-2 text-xs text-gray-600 dark:text-gray-400">
                                                <span class="text-green-600 dark:text-green-400">âœ“</span>
                                                <span>Well-tolerated</span>
                                            </div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-2">
                                            <a href="other.html" class="inline-flex items-center px-3 py-1.5 text-xs font-medium rounded-lg bg-gradient-to-r from-indigo-600 to-purple-600 text-white hover:from-indigo-700 hover:to-purple-700 transition-all">
                                                View Details
                                            </a>
                                            <a href="https://leaf.intelligence/search?q=ezetimibe" target="_blank" class="hidden inline-flex items-center px-3 py-1.5 text-xs font-medium rounded-lg border border-gray-300 dark:border-gray-600 text-gray-700 dark:text-gray-300 hover:bg-gray-50 dark:hover:bg-gray-800 transition-all">
                                                Leaf Intel
                                            </a>
                                        </div>
                                    </td>
                                </tr>

                                <!-- Pipeline: MK-0616 -->
                                <tr class="pipeline pcsk9 hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <div class="text-base font-medium text-gray-900 dark:text-white">MK-0616 (enplicitide)</div>
                                            <div class="text-sm text-indigo-600 dark:text-indigo-400">Merck</div>
                                            <div class="inline-block px-2 py-1 text-xs bg-gray-100 dark:bg-gray-800 text-gray-700 dark:text-gray-300 rounded">Oral PCSK9 Inhibitor (Macrocyclic Peptide)</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-amber-100 dark:bg-amber-900/30 text-amber-800 dark:text-amber-400">
                                                â§— Pipeline
                                            </span>
                                            <div class="text-xs text-gray-500 dark:text-gray-400">Phase 3 (17,000 pts)</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <div class="text-sm text-gray-900 dark:text-white">6-30 mg oral once daily</div>
                                            <div class="text-xs text-gray-500 dark:text-gray-400">First-in-class oral PCSK9i</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-2">
                                            <div class="w-full bg-gray-200 dark:bg-gray-700 rounded-full h-2">
                                                <div class="bg-gradient-to-r from-indigo-500 to-purple-500 h-2 rounded-full text-xs text-white text-center" style="width: 60%"></div>
                                            </div>
                                            <div class="text-xs text-gray-600 dark:text-gray-400">CORALreef outcomes 2029</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <div class="flex items-center gap-2 text-xs text-gray-600 dark:text-gray-400">
                                                <span class="text-purple-600 dark:text-purple-400">P3</span>
                                                <span>Phase 3 Aug 2023</span>
                                            </div>
                                            <div class="flex items-center gap-2 text-xs text-gray-600 dark:text-gray-400">
                                                <span class="text-blue-600 dark:text-blue-400">26</span>
                                                <span>Approval exp. 2025-26</span>
                                            </div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-2">
                                            <a href="MK-0616.html" class="inline-flex items-center px-3 py-1.5 text-xs font-medium rounded-lg bg-gradient-to-r from-indigo-600 to-purple-600 text-white hover:from-indigo-700 hover:to-purple-700 transition-all">
                                                View Details
                                            </a>
                                            <a href="https://leaf.intelligence/search?q=MK-0616" target="_blank" class="hidden inline-flex items-center px-3 py-1.5 text-xs font-medium rounded-lg border border-gray-300 dark:border-gray-600 text-gray-700 dark:text-gray-300 hover:bg-gray-50 dark:hover:bg-gray-800 transition-all">
                                                Leaf Intel
                                            </a>
                                        </div>
                                    </td>
                                </tr>

                                <!-- Pipeline: AZD0780 -->
                                <tr class="pipeline pcsk9 hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <div class="text-base font-medium text-gray-900 dark:text-white">AZD0780</div>
                                            <div class="text-sm text-indigo-600 dark:text-indigo-400">AstraZeneca</div>
                                            <div class="inline-block px-2 py-1 text-xs bg-gray-100 dark:bg-gray-800 text-gray-700 dark:text-gray-300 rounded">Oral PCSK9 Inhibitor (Small Molecule)</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-amber-100 dark:bg-amber-900/30 text-amber-800 dark:text-amber-400">
                                                â§— Pipeline
                                            </span>
                                            <div class="text-xs text-gray-500 dark:text-gray-400">Phase 2 Complete</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <div class="text-sm text-gray-900 dark:text-white">30 mg oral once daily</div>
                                            <div class="text-xs text-gray-500 dark:text-gray-400">Can be taken with/without food</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-2">
                                            <div class="w-full bg-gray-200 dark:bg-gray-700 rounded-full h-2">
                                                <div class="bg-gradient-to-r from-indigo-500 to-purple-500 h-2 rounded-full text-xs text-white text-center" style="width: 51%"></div>
                                            </div>
                                            <div class="text-xs text-gray-600 dark:text-gray-400">Alzheimer's biomarkerâ†“</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <div class="flex items-center gap-2 text-xs text-gray-600 dark:text-gray-400">
                                                <span class="text-blue-600 dark:text-blue-400">UK</span>
                                                <span>Innovation Passport</span>
                                            </div>
                                            <div class="flex items-center gap-2 text-xs text-gray-600 dark:text-gray-400">
                                                <span class="text-purple-600 dark:text-purple-400">P3</span>
                                                <span>Phase 3 in 2025</span>
                                            </div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-2">
                                            <a href="astra.html" class="inline-flex items-center px-3 py-1.5 text-xs font-medium rounded-lg bg-gradient-to-r from-indigo-600 to-purple-600 text-white hover:from-indigo-700 hover:to-purple-700 transition-all">
                                                View Details
                                            </a>
                                            <a href="https://leaf.intelligence/search?q=AZD0780" target="_blank" class="hidden inline-flex items-center px-3 py-1.5 text-xs font-medium rounded-lg border border-gray-300 dark:border-gray-600 text-gray-700 dark:text-gray-300 hover:bg-gray-50 dark:hover:bg-gray-800 transition-all">
                                                Leaf Intel
                                            </a>
                                        </div>
                                    </td>
                                </tr>

                                <!-- Pipeline: LIB003 -->
                                <tr class="pipeline pcsk9 hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <div class="text-base font-medium text-gray-900 dark:text-white">LIB003 (lerodalcibep)</div>
                                            <div class="text-sm text-indigo-600 dark:text-indigo-400">LIB Therapeutics</div>
                                            <div class="inline-block px-2 py-1 text-xs bg-gray-100 dark:bg-gray-800 text-gray-700 dark:text-gray-300 rounded">Monthly PCSK9 Inhibitor (Adnectin)</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-amber-100 dark:bg-amber-900/30 text-amber-800 dark:text-amber-400">
                                                â§— Pipeline
                                            </span>
                                            <div class="text-xs text-gray-500 dark:text-gray-400">Filing 2025</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <div class="text-sm text-gray-900 dark:text-white">300 mg SC monthly</div>
                                            <div class="text-xs text-gray-500 dark:text-gray-400">Small volume: 1.2 mL</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-2">
                                            <div class="w-full bg-gray-200 dark:bg-gray-700 rounded-full h-2">
                                                <div class="bg-gradient-to-r from-indigo-500 to-purple-500 h-2 rounded-full text-xs text-white text-center" style="width: 56%"></div>
                                            </div>
                                            <div class="text-xs text-gray-600 dark:text-gray-400">FDA Fast Track</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <div class="flex items-center gap-2 text-xs text-gray-600 dark:text-gray-400">
                                                <span class="text-purple-600 dark:text-purple-400">52</span>
                                                <span>52-week positive</span>
                                            </div>
                                            <div class="flex items-center gap-2 text-xs text-gray-600 dark:text-gray-400">
                                                <span class="text-green-600 dark:text-green-400">âœ“</span>
                                                <span>No immunogenicity</span>
                                            </div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-2">
                                            <a href="lib.html" class="inline-flex items-center px-3 py-1.5 text-xs font-medium rounded-lg bg-gradient-to-r from-indigo-600 to-purple-600 text-white hover:from-indigo-700 hover:to-purple-700 transition-all">
                                                View Details
                                            </a>
                                            <a href="https://leaf.intelligence/search?q=lerodalcibep" target="_blank" class="hidden inline-flex items-center px-3 py-1.5 text-xs font-medium rounded-lg border border-gray-300 dark:border-gray-600 text-gray-700 dark:text-gray-300 hover:bg-gray-50 dark:hover:bg-gray-800 transition-all">
                                                Leaf Intel
                                            </a>
                                        </div>
                                    </td>
                                </tr>

                                <!-- Pipeline: Obicetrapib -->
                                <tr class="pipeline other hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <div class="text-base font-medium text-gray-900 dark:text-white">Obicetrapib</div>
                                            <div class="text-sm text-indigo-600 dark:text-indigo-400">NewAmsterdam Pharma</div>
                                            <div class="inline-block px-2 py-1 text-xs bg-gray-100 dark:bg-gray-800 text-gray-700 dark:text-gray-300 rounded">CETP Inhibitor</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-amber-100 dark:bg-amber-900/30 text-amber-800 dark:text-amber-400">
                                                â§— Pipeline
                                            </span>
                                            <div class="text-xs text-gray-500 dark:text-gray-400">EMA Filed Aug 2025</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <div class="text-sm text-gray-900 dark:text-white">10 mg oral once daily</div>
                                            <div class="text-xs text-gray-500 dark:text-gray-400">Fixed-dose combo w/ ezetimibe</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-2">
                                            <div class="w-full bg-gray-200 dark:bg-gray-700 rounded-full h-2">
                                                <div class="bg-gradient-to-r from-indigo-500 to-purple-500 h-2 rounded-full text-xs text-white text-center" style="width: 45%"></div>
                                            </div>
                                            <div class="text-xs text-gray-600 dark:text-gray-400">HDL >100%â†‘</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <div class="flex items-center gap-2 text-xs text-gray-600 dark:text-gray-400">
                                                <span class="text-blue-600 dark:text-blue-400">EU</span>
                                                <span>EMA filing submitted</span>
                                            </div>
                                            <div class="flex items-center gap-2 text-xs text-gray-600 dark:text-gray-400">
                                                <span class="text-red-600 dark:text-red-400">CV</span>
                                                <span>PREVAIL ongoing</span>
                                            </div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-2">
                                            <a href="other.html" class="inline-flex items-center px-3 py-1.5 text-xs font-medium rounded-lg bg-gradient-to-r from-indigo-600 to-purple-600 text-white hover:from-indigo-700 hover:to-purple-700 transition-all">
                                                View Details
                                            </a>
                                            <a href="https://leaf.intelligence/search?q=obicetrapib" target="_blank" class="hidden inline-flex items-center px-3 py-1.5 text-xs font-medium rounded-lg border border-gray-300 dark:border-gray-600 text-gray-700 dark:text-gray-300 hover:bg-gray-50 dark:hover:bg-gray-800 transition-all">
                                                Leaf Intel
                                            </a>
                                        </div>
                                    </td>
                                </tr>

                                <!-- Pipeline: VERVE-101 -->
                                <tr class="pipeline other hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <div class="text-base font-medium text-gray-900 dark:text-white">VERVE-101</div>
                                            <div class="text-sm text-indigo-600 dark:text-indigo-400">Verve Therapeutics (Acquired by Eli Lilly)</div>
                                            <div class="inline-block px-2 py-1 text-xs bg-gray-100 dark:bg-gray-800 text-gray-700 dark:text-gray-300 rounded">PCSK9 Gene Editing (Base Editor)</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-amber-100 dark:bg-amber-900/30 text-amber-800 dark:text-amber-400">
                                                â§— Pipeline
                                            </span>
                                            <div class="text-xs text-gray-500 dark:text-gray-400">Phase 1</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <div class="text-sm text-gray-900 dark:text-white">One-time IV infusion</div>
                                            <div class="text-xs text-gray-500 dark:text-gray-400">Permanent PCSK9 knockout</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-2">
                                            <div class="w-full bg-gray-200 dark:bg-gray-700 rounded-full h-2">
                                                <div class="bg-gradient-to-r from-indigo-500 to-purple-500 h-2 rounded-full text-xs text-white text-center" style="width: 60%"></div>
                                            </div>
                                            <div class="text-xs text-gray-600 dark:text-gray-400">Permanent effect</div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-1">
                                            <div class="flex items-center gap-2 text-xs text-gray-600 dark:text-gray-400">
                                                <span class="text-green-600 dark:text-green-400">$B</span>
                                                <span>$1.3B acquisition</span>
                                            </div>
                                            <div class="flex items-center gap-2 text-xs text-gray-600 dark:text-gray-400">
                                                <span class="text-green-600 dark:text-green-400">âœ“</span>
                                                <span>FDA hold lifted</span>
                                            </div>
                                        </div>
                                    </td>
                                    <td class="px-6 py-4">
                                        <div class="space-y-2">
                                            <a href="verve.html" class="inline-flex items-center px-3 py-1.5 text-xs font-medium rounded-lg bg-gradient-to-r from-indigo-600 to-purple-600 text-white hover:from-indigo-700 hover:to-purple-700 transition-all">
                                                View Details
                                            </a>
                                            <a href="https://leaf.intelligence/search?q=VERVE-101" target="_blank" class="hidden inline-flex items-center px-3 py-1.5 text-xs font-medium rounded-lg border border-gray-300 dark:border-gray-600 text-gray-700 dark:text-gray-300 hover:bg-gray-50 dark:hover:bg-gray-800 transition-all">
                                                Leaf Intel
                                            </a>
                                        </div>
                                    </td>
                                </tr>
                            </tbody>
                        </table>
                    </div>
                </div>

                <!-- Stats Bar -->
                <div class="glass rounded-2xl p-6 mt-6 border border-gray-200 dark:border-gray-700">
                    <div class="flex flex-wrap gap-8 justify-center">
                        <div class="text-center">
                            <div class="text-2xl font-bold text-indigo-600 dark:text-indigo-400">11</div>
                            <div class="text-xs text-gray-600 dark:text-gray-400 uppercase tracking-wider">Total Therapies</div>
                        </div>
                        <div class="text-center">
                            <div class="text-2xl font-bold text-green-600 dark:text-green-400">5</div>
                            <div class="text-xs text-gray-600 dark:text-gray-400 uppercase tracking-wider">Approved</div>
                        </div>
                        <div class="text-center">
                            <div class="text-2xl font-bold text-amber-600 dark:text-amber-400">6</div>
                            <div class="text-xs text-gray-600 dark:text-gray-400 uppercase tracking-wider">Pipeline</div>
                        </div>
                        <div class="text-center">
                            <div class="text-2xl font-bold text-purple-600 dark:text-purple-400">8</div>
                            <div class="text-xs text-gray-600 dark:text-gray-400 uppercase tracking-wider">PCSK9 Inhibitors</div>
                        </div>
                        <div class="text-center">
                            <div class="text-2xl font-bold text-blue-600 dark:text-blue-400">3</div>
                            <div class="text-xs text-gray-600 dark:text-gray-400 uppercase tracking-wider">Oral Options</div>
                        </div>
                    </div>
                </div>
            </div>
        </div>

        <!-- Comparison Tab -->
        <div class="tab-content hidden" id="comparison">
            <div class="max-w-7xl mx-auto px-4 sm:px-6 lg:px-8 py-8">
                <!-- Comprehensive Feature Comparison -->
                <div class="glass rounded-2xl mb-8 border border-gray-200 dark:border-gray-700">
                    <div class="p-6 border-b border-gray-200 dark:border-gray-700">
                        <h3 class="text-xl font-light text-gray-900 dark:text-white flex items-center gap-3">
                            <svg class="w-6 h-6" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2">
                                <path d="M9 11H3V21H9V11Z M15 3H9V21H15V3Z M21 7H15V21H21V7Z" stroke-linecap="round" stroke-linejoin="round"/>
                            </svg>
                            Comprehensive Feature Comparison
                        </h3>
                    </div>
                    
                    <div class="p-6">
                        <div class="p-4 bg-blue-50 dark:bg-blue-900/20 rounded-lg mb-6">
                            <p class="text-sm text-gray-700 dark:text-gray-300">
                                <strong>Guide:</strong> This table compares all therapies across key dimensions. Inclisiran (reference) is highlighted. 
                                Click any row for detailed information. Green badges indicate proven CV outcomes.
                            </p>
                        </div>
                        
                        <div class="overflow-x-auto">
                            <table class="w-full">
                                <thead>
                                    <tr class="bg-gray-50 dark:bg-gray-800">
                                        <th class="px-4 py-3 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Therapy</th>
                                        <th class="px-4 py-3 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Mechanism</th>
                                        <th class="px-4 py-3 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Dosing</th>
                                        <th class="px-4 py-3 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">LDL Reduction</th>
                                        <th class="px-4 py-3 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">CV Outcomes</th>
                                        <th class="px-4 py-3 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Annual Cost</th>
                                        <th class="px-4 py-3 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Status</th>
                                    </tr>
                                </thead>
                                <tbody class="divide-y divide-gray-200 dark:divide-gray-700">
                                    <tr class="bg-amber-50 dark:bg-amber-900/10 hover:bg-amber-100 dark:hover:bg-amber-900/20 transition-colors">
                                        <td class="px-4 py-3 text-sm font-medium text-gray-900 dark:text-white">Inclisiran</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">PCSK9 siRNA</td>
                                        <td class="px-4 py-3 text-sm font-medium text-gray-900 dark:text-white">2x/year SC</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">50-52%</td>
                                        <td class="px-4 py-3">
                                            <span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-amber-100 dark:bg-amber-900/30 text-amber-800 dark:text-amber-400">
                                                Pending (2026)
                                            </span>
                                        </td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">~$6,500</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Approved</td>
                                    </tr>
                                    <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors cursor-pointer" onclick="window.location.href='repatha-details.html'">
                                        <td class="px-4 py-3 text-sm text-gray-900 dark:text-white">Repatha</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">PCSK9 mAb</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Q2W or monthly SC</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">60%</td>
                                        <td class="px-4 py-3">
                                            <span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-green-100 dark:bg-green-900/30 text-green-800 dark:text-green-400">
                                                âœ“ 15% MACEâ†“
                                            </span>
                                        </td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">~$5,800</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Approved</td>
                                    </tr>
                                    <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors cursor-pointer" onclick="window.location.href='praluent-details.html'">
                                        <td class="px-4 py-3 text-sm text-gray-900 dark:text-white">Praluent</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">PCSK9 mAb</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Q2W or monthly SC</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">50-60%</td>
                                        <td class="px-4 py-3">
                                            <span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-green-100 dark:bg-green-900/30 text-green-800 dark:text-green-400">
                                                âœ“ 15% MACE, 15% mortalityâ†“
                                            </span>
                                        </td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">~$5,850</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Approved</td>
                                    </tr>
                                    <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                        <td class="px-4 py-3 text-sm text-gray-900 dark:text-white">MK-0616</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Oral PCSK9i</td>
                                        <td class="px-4 py-3 text-sm font-medium text-gray-900 dark:text-white">Daily oral</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">60%</td>
                                        <td class="px-4 py-3">
                                            <span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-amber-100 dark:bg-amber-900/30 text-amber-800 dark:text-amber-400">
                                                Trial 2029
                                            </span>
                                        </td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">TBD</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Phase 3</td>
                                    </tr>
                                    <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                        <td class="px-4 py-3 text-sm text-gray-900 dark:text-white">Bempedoic Acid</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">ACL inhibitor</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Daily oral</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">18-25%</td>
                                        <td class="px-4 py-3">
                                            <span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-green-100 dark:bg-green-900/30 text-green-800 dark:text-green-400">
                                                âœ“ 13% MACE, 23% MIâ†“
                                            </span>
                                        </td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">~$4,800</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Approved</td>
                                    </tr>
                                    <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                        <td class="px-4 py-3 text-sm text-gray-900 dark:text-white">Ezetimibe</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">NPC1L1 inhibitor</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Daily oral</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">15-25%</td>
                                        <td class="px-4 py-3">
                                            <span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-green-100 dark:bg-green-900/30 text-green-800 dark:text-green-400">
                                                âœ“ 6-7% MACEâ†“
                                            </span>
                                        </td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Generic (~$120)</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Approved</td>
                                    </tr>
                                    <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                        <td class="px-4 py-3 text-sm text-gray-900 dark:text-white">VERVE-101</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Gene editing</td>
                                        <td class="px-4 py-3 text-sm font-medium text-gray-900 dark:text-white">One-time</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">60% (permanent)</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">N/A</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">>$100,000?</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Phase 1</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>
                    </div>
                </div>

                <!-- Dosing Frequency Analysis -->
                <div class="glass rounded-2xl mb-8 border border-gray-200 dark:border-gray-700">
                    <div class="p-6 border-b border-gray-200 dark:border-gray-700">
                        <h3 class="text-xl font-light text-gray-900 dark:text-white flex items-center gap-3">
                            <svg class="w-6 h-6" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2">
                                <path d="M12 2L2 7V12C2 16.55 4.84 20.74 9 22C13.16 20.74 22 16.55 22 12V7L12 2Z" stroke-linecap="round" stroke-linejoin="round"/>
                            </svg>
                            Dosing Frequency Analysis
                        </h3>
                    </div>
                    
                    <div class="p-6 grid grid-cols-2 md:grid-cols-4 gap-4">
                        <div class="bg-gradient-to-br from-purple-50 to-purple-100 dark:from-purple-900/20 dark:to-purple-800/20 p-6 rounded-lg text-center">
                            <div class="text-3xl font-bold text-purple-600 dark:text-purple-400">1</div>
                            <div class="text-sm text-gray-700 dark:text-gray-300 mt-2">One-Time (Gene editing)</div>
                        </div>
                        <div class="bg-gradient-to-br from-green-50 to-green-100 dark:from-green-900/20 dark:to-green-800/20 p-6 rounded-lg text-center">
                            <div class="text-3xl font-bold text-green-600 dark:text-green-400">2</div>
                            <div class="text-sm text-gray-700 dark:text-gray-300 mt-2">Per Year (Inclisiran)</div>
                        </div>
                        <div class="bg-gradient-to-br from-blue-50 to-blue-100 dark:from-blue-900/20 dark:to-blue-800/20 p-6 rounded-lg text-center">
                            <div class="text-3xl font-bold text-blue-600 dark:text-blue-400">12</div>
                            <div class="text-sm text-gray-700 dark:text-gray-300 mt-2">Monthly (LIB003, Evinacumab)</div>
                        </div>
                        <div class="bg-gradient-to-br from-amber-50 to-amber-100 dark:from-amber-900/20 dark:to-amber-800/20 p-6 rounded-lg text-center">
                            <div class="text-3xl font-bold text-amber-600 dark:text-amber-400">365</div>
                            <div class="text-sm text-gray-700 dark:text-gray-300 mt-2">Daily (All oral agents)</div>
                        </div>
                    </div>
                </div>

                <!-- Clinical Trials Tracker -->
                <div class="glass rounded-2xl mb-8 border border-gray-200 dark:border-gray-700">
                    <div class="p-6 border-b border-gray-200 dark:border-gray-700">
                        <h3 class="text-xl font-light text-gray-900 dark:text-white flex items-center gap-3 mb-4">
                            <svg class="w-6 h-6" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2">
                                <path d="M9 5H7C5.89543 5 5 5.89543 5 7V19C5 20.1046 5.89543 21 7 21H17C18.1046 21 19 20.1046 19 19V7C19 5.89543 18.1046 5 17 5H15" stroke-linecap="round" stroke-linejoin="round"/>
                                <path d="M9 5C9 3.89543 9.89543 3 11 3H13C14.1046 3 15 3.89543 15 5V7H9V5Z" stroke-linecap="round" stroke-linejoin="round"/>
                            </svg>
                            Clinical Trials Tracker
                        </h3>
                        
                        <div class="flex flex-wrap gap-2">
                            <button class="filter-btn px-4 py-2 rounded-lg text-sm font-medium transition-all bg-indigo-600 text-white" onclick="filterTrials('all', event)">
                                All Trials
                            </button>
                            <button class="filter-btn px-4 py-2 rounded-lg text-sm font-medium transition-all bg-gray-100 dark:bg-gray-800 text-gray-700 dark:text-gray-300 hover:bg-gray-200 dark:hover:bg-gray-700" onclick="filterTrials('ongoing', event)">
                                Ongoing
                            </button>
                            <button class="filter-btn px-4 py-2 rounded-lg text-sm font-medium transition-all bg-gray-100 dark:bg-gray-800 text-gray-700 dark:text-gray-300 hover:bg-gray-200 dark:hover:bg-gray-700" onclick="filterTrials('complete', event)">
                                Complete
                            </button>
                            <button class="filter-btn px-4 py-2 rounded-lg text-sm font-medium transition-all bg-gray-100 dark:bg-gray-800 text-gray-700 dark:text-gray-300 hover:bg-gray-200 dark:hover:bg-gray-700" onclick="filterTrials('phase1', event)">
                                Phase 1
                            </button>
                        </div>
                    </div>
                    
                    <div class="p-6">
                        <div class="overflow-x-auto">
                            <table class="w-full" id="trials-table">
                                <thead>
                                    <tr class="bg-gray-50 dark:bg-gray-800">
                                        <th class="px-4 py-3 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Trial Name</th>
                                        <th class="px-4 py-3 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Drug</th>
                                        <th class="px-4 py-3 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Status</th>
                                        <th class="px-4 py-3 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">N</th>
                                        <th class="px-4 py-3 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Primary Endpoint</th>
                                        <th class="px-4 py-3 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Timeline</th>
                                    </tr>
                                </thead>
                                <tbody class="divide-y divide-gray-200 dark:divide-gray-700">
                                    <tr data-status="ongoing" class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                        <td class="px-4 py-3 text-sm font-medium text-gray-900 dark:text-white">ORION-4</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Inclisiran</td>
                                        <td class="px-4 py-3">
                                            <span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-amber-100 dark:bg-amber-900/30 text-amber-800 dark:text-amber-400">
                                                Ongoing
                                            </span>
                                        </td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">15,000</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">CV outcomes</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Results ~2026</td>
                                    </tr>
                                    <tr data-status="complete" class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                        <td class="px-4 py-3 text-sm font-medium text-gray-900 dark:text-white">FOURIER</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Repatha</td>
                                        <td class="px-4 py-3">
                                            <span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-green-100 dark:bg-green-900/30 text-green-800 dark:text-green-400">
                                                Complete
                                            </span>
                                        </td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">27,564</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">MACE</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">15% MACE reduction</td>
                                    </tr>
                                    <tr data-status="complete" class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                        <td class="px-4 py-3 text-sm font-medium text-gray-900 dark:text-white">ODYSSEY Outcomes</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Praluent</td>
                                        <td class="px-4 py-3">
                                            <span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-green-100 dark:bg-green-900/30 text-green-800 dark:text-green-400">
                                                Complete
                                            </span>
                                        </td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">18,924</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">MACE</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">15% MACE, 15% mortalityâ†“</td>
                                    </tr>
                                    <tr data-status="ongoing" class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                        <td class="px-4 py-3 text-sm font-medium text-gray-900 dark:text-white">CORALreef Outcomes</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">MK-0616</td>
                                        <td class="px-4 py-3">
                                            <span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-amber-100 dark:bg-amber-900/30 text-amber-800 dark:text-amber-400">
                                                Enrolling
                                            </span>
                                        </td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">14,000</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">CV outcomes</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Results ~2029</td>
                                    </tr>
                                    <tr data-status="complete" class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                        <td class="px-4 py-3 text-sm font-medium text-gray-900 dark:text-white">CLEAR Outcomes</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Bempedoic Acid</td>
                                        <td class="px-4 py-3">
                                            <span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-green-100 dark:bg-green-900/30 text-green-800 dark:text-green-400">
                                                Complete
                                            </span>
                                        </td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">13,970</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">4-point MACE</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">13% MACE, 23% MIâ†“</td>
                                    </tr>
                                    <tr data-status="phase1" class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                        <td class="px-4 py-3 text-sm font-medium text-gray-900 dark:text-white">HEART-1</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">VERVE-101</td>
                                        <td class="px-4 py-3">
                                            <span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-blue-100 dark:bg-blue-900/30 text-blue-800 dark:text-blue-400">
                                                Phase 1
                                            </span>
                                        </td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">~40</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Safety/LDL</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Ongoing</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>
                    </div>
                </div>

                <!-- Safety Profiles -->
                <div class="glass rounded-2xl mb-8 border border-gray-200 dark:border-gray-700">
                    <div class="p-6 border-b border-gray-200 dark:border-gray-700">
                        <h3 class="text-xl font-light text-gray-900 dark:text-white flex items-center gap-3">
                            <svg class="w-6 h-6" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2">
                                <path d="M12 22C17.5228 22 22 17.5228 22 12C22 6.47715 17.5228 2 12 2C6.47715 2 2 6.47715 2 12C2 17.5228 6.47715 22 12 22Z" stroke-linecap="round" stroke-linejoin="round"/>
                                <path d="M12 8V12M12 16H12.01" stroke-linecap="round" stroke-linejoin="round"/>
                            </svg>
                            Safety Profiles
                        </h3>
                    </div>
                    
                    <div class="p-6">
                        <div class="overflow-x-auto">
                            <table class="w-full">
                                <thead>
                                    <tr class="bg-gray-50 dark:bg-gray-800">
                                        <th class="px-4 py-3 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Therapy</th>
                                        <th class="px-4 py-3 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Common AEs</th>
                                        <th class="px-4 py-3 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Unique Risks</th>
                                        <th class="px-4 py-3 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Long-term Data</th>
                                    </tr>
                                </thead>
                                <tbody class="divide-y divide-gray-200 dark:divide-gray-700">
                                    <tr class="bg-amber-50 dark:bg-amber-900/10 hover:bg-amber-100 dark:hover:bg-amber-900/20 transition-colors">
                                        <td class="px-4 py-3 text-sm font-medium text-gray-900 dark:text-white">Inclisiran</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">ISR ~5%</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">None identified</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">4+ years</td>
                                    </tr>
                                    <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                        <td class="px-4 py-3 text-sm text-gray-900 dark:text-white">PCSK9 mAbs</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">ISR 2-4%, nasopharyngitis</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">None (8+ year record)</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Excellent</td>
                                    </tr>
                                    <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                        <td class="px-4 py-3 text-sm text-gray-900 dark:text-white">Bempedoic Acid</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Well-tolerated</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Gout 3.5%, tendon rupture 0.5%</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">5+ years</td>
                                    </tr>
                                    <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                        <td class="px-4 py-3 text-sm text-gray-900 dark:text-white">Statins</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Muscle pain 5-10%</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Rare rhabdo, slight diabetes risk</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">30+ years</td>
                                    </tr>
                                    <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                        <td class="px-4 py-3 text-sm text-gray-900 dark:text-white">Oral PCSK9i</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Similar to placebo</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">TBD (limited data)</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Limited</td>
                                    </tr>
                                    <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                        <td class="px-4 py-3 text-sm text-gray-900 dark:text-white">Gene Editing</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Under evaluation</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">Off-target edits (theoretical)</td>
                                        <td class="px-4 py-3 text-sm text-gray-600 dark:text-gray-400">None</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>
                    </div>
                </div>

                <!-- Market Access & Payer Considerations -->
                <div class="glass rounded-2xl mb-8 border border-gray-200 dark:border-gray-700">
                    <div class="p-6 border-b border-gray-200 dark:border-gray-700">
                        <h3 class="text-xl font-light text-gray-900 dark:text-white flex items-center gap-3">
                            <svg class="w-6 h-6" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2">
                                <path d="M12 2V22M17 5H9.5C8.57174 5 7.6815 5.36875 7.02513 6.02513C6.36875 6.6815 6 7.57174 6 8.5C6 9.42826 6.36875 10.3185 7.02513 10.9749C7.6815 11.6313 8.57174 12 9.5 12H14.5C15.4283 12 16.3185 12.3687 16.9749 13.0251C17.6313 13.6815 18 14.5717 18 15.5C18 16.4283 17.6313 17.3185 16.9749 17.9749C16.3185 18.6313 15.4283 19 14.5 19H6" stroke-linecap="round" stroke-linejoin="round"/>
                            </svg>
                            Market Access & Payer Considerations
                        </h3>
                    </div>
                    
                    <div class="p-6">
                        <div class="p-4 bg-blue-50 dark:bg-blue-900/20 rounded-lg">
                            <p class="text-sm text-gray-700 dark:text-gray-300 mb-3">
                                <strong>Typical Step Therapy Sequence:</strong>
                            </p>
                            <ol class="space-y-2 text-sm text-gray-600 dark:text-gray-400">
                                <li class="flex items-start">
                                    <span class="flex-shrink-0 w-6 h-6 bg-indigo-600 text-white rounded-full flex items-center justify-center text-xs mr-2">1</span>
                                    <span>Maximally tolerated statin (generic, ~$5-10/month)</span>
                                </li>
                                <li class="flex items-start">
                                    <span class="flex-shrink-0 w-6 h-6 bg-indigo-600 text-white rounded-full flex items-center justify-center text-xs mr-2">2</span>
                                    <span>Add ezetimibe (generic, ~$10-20/month)</span>
                                </li>
                                <li class="flex items-start">
                                    <span class="flex-shrink-0 w-6 h-6 bg-indigo-600 text-white rounded-full flex items-center justify-center text-xs mr-2">3</span>
                                    <span>Consider bempedoic acid (if statin intolerant, ~$400/month)</span>
                                </li>
                                <li class="flex items-start">
                                    <span class="flex-shrink-0 w-6 h-6 bg-indigo-600 text-white rounded-full flex items-center justify-center text-xs mr-2">4</span>
                                    <span>PCSK9 inhibitor consideration (if LDL still >70-100 mg/dL)</span>
                                </li>
                                <li class="flex items-start">
                                    <span class="flex-shrink-0 w-6 h-6 bg-indigo-600 text-white rounded-full flex items-center justify-center text-xs mr-2">5</span>
                                    <span>Choice between: Inclisiran (2x/year), mAbs (monthly/biweekly), or oral PCSK9i (when available)</span>
                                </li>
                            </ol>
                        </div>
                    </div>
                </div>

                <!-- 5-10 Year Market Evolution -->
                <div class="glass rounded-2xl border border-gray-200 dark:border-gray-700">
                    <div class="p-6 border-b border-gray-200 dark:border-gray-700">
                        <h3 class="text-xl font-light text-gray-900 dark:text-white flex items-center gap-3">
                            <svg class="w-6 h-6" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2">
                                <path d="M12 5V19M5 12H19" stroke-linecap="round" stroke-linejoin="round"/>
                            </svg>
                            5-10 Year Market Evolution
                        </h3>
                    </div>
                    
                    <div class="p-6">
                        <div class="relative pl-8">
                            <!-- Timeline line -->
                            <div class="absolute left-3 top-0 bottom-0 w-0.5 bg-gradient-to-b from-transparent via-indigo-300 dark:via-indigo-600 to-transparent"></div>
                            
                            <!-- Timeline items -->
                            <div class="relative mb-8">
                                <div class="absolute -left-5 w-4 h-4 bg-indigo-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                                <div class="ml-6">
                                    <div class="text-xs font-medium text-indigo-600 dark:text-indigo-400 mb-1">2025-2027</div>
                                    <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Oral Revolution</div>
                                    <div class="text-xs text-gray-600 dark:text-gray-400">
                                        â€¢ MK-0616, AZD0780 enter market<br>
                                        â€¢ LIB003 approved as monthly option<br>
                                        â€¢ Inclisiran ORION-4 validates CV benefit<br>
                                        â€¢ Price competition intensifies
                                    </div>
                                </div>
                            </div>
                            
                            <div class="relative mb-8">
                                <div class="absolute -left-5 w-4 h-4 bg-amber-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                                <div class="ml-6">
                                    <div class="text-xs font-medium text-amber-600 dark:text-amber-400 mb-1">2028-2030</div>
                                    <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Biosimilar Era</div>
                                    <div class="text-xs text-gray-600 dark:text-gray-400">
                                        â€¢ PCSK9 mAb biosimilars arrive<br>
                                        â€¢ Oral PCSK9i dominate new prescriptions<br>
                                        â€¢ Gene editing potentially approved for FH<br>
                                        â€¢ Combination pills emerge
                                    </div>
                                </div>
                            </div>
                            
                            <div class="relative">
                                <div class="absolute -left-5 w-4 h-4 bg-green-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                                <div class="ml-6">
                                    <div class="text-xs font-medium text-green-600 dark:text-green-400 mb-1">2030-2035</div>
                                    <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Precision Medicine</div>
                                    <div class="text-xs text-gray-600 dark:text-gray-400">
                                        â€¢ Personalized therapy selection<br>
                                        â€¢ Gene editing for broader populations<br>
                                        â€¢ Ultra-low cost generics<br>
                                        â€¢ Primary prevention expansion
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </div>

    <!-- JavaScript -->
    <script>
        function toggleTheme() {
            document.body.classList.toggle('dark');
            localStorage.setItem('theme', document.body.classList.contains('dark') ? 'dark' : 'light');
        }

        // Load saved theme or default to light
        if (localStorage.getItem('theme') === 'dark' || (!localStorage.getItem('theme') && window.matchMedia('(prefers-color-scheme: dark)').matches)) {
            document.body.classList.add('dark');
        }

        function showTab(tabName) {
            // Hide all tabs
            const tabs = document.querySelectorAll('.tab-content');
            tabs.forEach(tab => {
                tab.classList.add('hidden');
                tab.classList.remove('active');
            });
            
            // Remove active from all nav tabs
            const navTabs = document.querySelectorAll('.nav-tab');
            navTabs.forEach(tab => tab.classList.remove('active'));
            
            // Show selected tab
            const selectedTab = document.getElementById(tabName);
            if (selectedTab) {
                selectedTab.classList.remove('hidden');
                selectedTab.classList.add('active');
            }
            
            // Mark nav tab as active
            const activeButton = document.querySelector(`.nav-tab[onclick*="${tabName}"]`);
            if (activeButton) {
                activeButton.classList.add('active');
                activeButton.classList.add('bg-white', 'dark:bg-gray-700', 'text-indigo-600', 'dark:text-indigo-400', 'shadow-md');
                activeButton.classList.remove('text-gray-600', 'dark:text-gray-400');
            }
        }

        function filterTable(filter, event) {
            // Update active button
            const buttons = event.target.parentElement.querySelectorAll('.filter-btn');
            buttons.forEach(btn => {
                btn.classList.remove('bg-indigo-600', 'text-white');
                btn.classList.add('bg-gray-100', 'dark:bg-gray-800', 'text-gray-700', 'dark:text-gray-300');
            });
            event.target.classList.remove('bg-gray-100', 'dark:bg-gray-800', 'text-gray-700', 'dark:text-gray-300');
            event.target.classList.add('bg-indigo-600', 'text-white');

            // Filter rows
            const rows = document.querySelectorAll('#approved tbody tr');
            rows.forEach((row, index) => {
                // Reset animation
                row.style.animation = 'none';
                
                setTimeout(() => {
                    if (filter === 'all') {
                        row.style.display = '';
                    } else if (filter === 'approved' && row.classList.contains('approved')) {
                        row.style.display = '';
                    } else if (filter === 'pipeline' && row.classList.contains('pipeline')) {
                        row.style.display = '';
                    } else if (filter === 'pcsk9' && row.classList.contains('pcsk9')) {
                        row.style.display = '';
                    } else if (filter === 'other' && row.classList.contains('other')) {
                        row.style.display = '';
                    } else {
                        row.style.display = 'none';
                    }
                    
                    // Reapply animation to visible rows
                    if (row.style.display !== 'none') {
                        row.style.animation = `fadeInRow 0.3s ease forwards`;
                        row.style.animationDelay = `${index * 0.05}s`;
                    }
                }, 10);
            });

            // Update stats
            updateStats(filter);
        }

        function updateStats(filter) {
            const rows = document.querySelectorAll('#approved tbody tr');
            let visibleCount = 0;
            let approvedCount = 0;
            let pipelineCount = 0;

            rows.forEach(row => {
                if (filter === 'all' || 
                    (filter === 'approved' && row.classList.contains('approved')) ||
                    (filter === 'pipeline' && row.classList.contains('pipeline')) ||
                    (filter === 'pcsk9' && row.classList.contains('pcsk9')) ||
                    (filter === 'other' && row.classList.contains('other'))) {
                    visibleCount++;
                    if (row.classList.contains('approved')) approvedCount++;
                    if (row.classList.contains('pipeline')) pipelineCount++;
                }
            });

            // Update stats display if needed
            const statValues = document.querySelectorAll('.stat-value');
            if (statValues.length > 0 && filter !== 'all') {
                statValues[0].textContent = visibleCount;
                statValues[0].style.animation = 'pulse 0.5s ease';
            }
        }

        function filterTrials(filter, event) {
            // Update active button
            const buttons = event.target.parentElement.querySelectorAll('.filter-btn');
            buttons.forEach(btn => {
                btn.classList.remove('bg-indigo-600', 'text-white');
                btn.classList.add('bg-gray-100', 'dark:bg-gray-800', 'text-gray-700', 'dark:text-gray-300');
            });
            event.target.classList.remove('bg-gray-100', 'dark:bg-gray-800', 'text-gray-700', 'dark:text-gray-300');
            event.target.classList.add('bg-indigo-600', 'text-white');

            // Filter rows
            const rows = document.querySelectorAll('#trials-table tbody tr');
            rows.forEach(row => {
                const status = row.getAttribute('data-status');
                if (filter === 'all') {
                    row.style.display = '';
                } else if (filter === status) {
                    row.style.display = '';
                } else {
                    row.style.display = 'none';
                }
            });
        }

        // Initialize on load
        document.addEventListener('DOMContentLoaded', function() {
            // Set initial active tab styling
            const activeTab = document.querySelector('.nav-tab.active');
            if (activeTab) {
                activeTab.classList.add('bg-white', 'dark:bg-gray-700', 'text-indigo-600', 'dark:text-indigo-400', 'shadow-md');
                activeTab.classList.remove('text-gray-600', 'dark:text-gray-400');
            }
        });
    </script>
</body>
</html>